Submitted:
26 February 2026
Posted:
27 February 2026
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. An Overview of Insulin Function and Its Role in Metabolism
3. Cognitive Deterioration in the Context of Metabolic Diseases
4. The Complex Interplay Between the Individual Components of the Metabolic Syndrome
4.1. Obesity and Metabolic Syndrome
4.2. Key Insulin-Target Tissues
4.2.1. Hepatic Tissue InsR
4.2.2. Adipose Tissue InsR
Visfatin
Fetuin-A
Vaspin
Skeletal muscle InsR
Irisin
Myonectin
Myokine IL-6
4.3. The Roles of Angiotensin-Related Molecules
4.4. Vascular Cognitive Impairment and Vascular Dementia
5. Ion Channels Play an Important Role in the Development and Progression of MetS
5.1. Potassium Channels
5.2. Sodium Channels
5.3. Transient Receptor Potential (TRP) Isoforms in Metabolic Syndrome
6. Age-Dependent Changes in Cell Remodeling and Herbs That Influence These Changes at the Molecular Level
6.1. Genomic Instability
6.2. Telomere Attrition
6.3. Epigenetic Alterations
6.4. Loss of Proteostasis
6.5. Mitochondrial Dysfunction
6.6. Cellular Senescence
6.7. Deregulated Nutrient Sensing
6.8. Stem Cell Exhaustion
6.9. Altered Intercellular Communication
7. Traditional Anti-Aging Medicines with the Potential to Be Translated into Effective Treatments for MetS-Induced Cognitive Decline
8. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
| ADA | American Diabetes Association |
| AMPK | AMP-activated protein kinase |
| AngII | Angiotensin II |
| AT1R | Angiotensin II type 1 receptor |
| BMI | Body mass index |
| CVD | Cardiovascular disease |
| CNS | Central nervous system |
| DAG | diacylglycerol |
| DFI | DNA fragmentation index |
| DNMT | DNA methyltransferase |
| EGCG | Epigallocatechin gallate |
| EVs | Extracellular vesicles |
| FOXO | Forkhead box O |
| GPCRs | G protein−coupled receptors |
| GSK3β | Glycogen synthase kinase 3 beta |
| HDAC | Histone deacetylase |
| HDL | High-density lipoprotein |
| IGF-1 | Insulin-like growth factor 1 |
| IGF-2 | Insulin-like growth factor 2 |
| IP3 | Inositol trisphosphate |
| IRS-1 | Insulin receptor substrates 1 |
| IRS-2 | Insulin receptor substrates 2 |
| InsR | Insulin resistance |
| IRs | Insulin receptors |
| MAPK | Mitogen-activated protein kinase |
| MASH | Metabolic dysfunction–associated steatohepatitis |
| MASLD | Metabolic dysfunction-associated steatotic liver disease |
| MetS | Metabolic syndrome |
| MMPs | Matrix metalloproteinases |
| mTOR | Mammalian target of rapamycin |
| NO | Nitic oxide |
| PBMCs | Peripheral blood mononuclear cells |
| PLC | Phospholipase C |
| PI3K | Phosphatidylinositol 3-kinase |
| RAS | Renin−angiotensin−system |
| RCT | Randomized controlled trial |
| ROS | Reactive oxygen species |
| SASP | Senescence-associated secretory phenotype |
| SIRT | Sirtuin |
| SOD | Superoxide dismutase |
| TBC1D4 | TBC1 domain family member 4 |
| NF-κB | Transcription factor nuclear factor-κB |
| TRP | Transient receptor potential |
| TSC1 | Tuberous sclerosis complex 1 |
| TSC2 | Tuberous sclerosis complex 2 |
| T2DM | Type 2 diabetes mellitus |
| TNF-α | Tumor necrosis factor−α |
| UKPDS | United Kingdom Prospective Diabetes Study |
| UN | United Nation |
References
- World Population Prospects, United Nations ( UN ), Population ages 65 and above (% of total population). Available online: https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS (accessed on 07 January 2026).
- Roberts, W.A.O., U.S.; Blakeslee, L.; and Rabe, A.M., The Population 65 Years and Older in the United States: 2016. United States Census Bureau. United States Census Bureau, 2018. Available online: https://www.govinfo.gov/content/pkg/GOVPUB-C3-PURL-gpo112762/pdf/GOVPUB-C3-PURL-gpo112762.pdf.
- Ortman, J.; Velkoff, V.; Hogan, H. An aging nation: The older population in the United States. In Current population reports; US Census Bureau, 2014. [Google Scholar]
- Yaffe, K. Metabolic syndrome and cognitive decline. Curr Alzheimer Res 2007, 4((2)), 123–126. [Google Scholar] [CrossRef]
- Jenkins, T.A. Metabolic Syndrome and Vascular-Associated Cognitive Impairment: a Focus on Preclinical Investigations. Current Diabetes Reports 2022, 22((8)), 333–340. [Google Scholar] [CrossRef] [PubMed]
- Mok, V.C.T.; Cai, Y.; Markus, H.S. Vascular cognitive impairment and dementia: Mechanisms, treatment, and future directions. Int J Stroke 2024, 19((8)), 838–856. [Google Scholar] [CrossRef] [PubMed]
- Chantler, P.D.; Shrader, C.D.; Tabone, L.E.; d'Audiffret, A.C.; Huseynova, K.; Brooks, S.D.; Branyan, K.W.; Grogg, K.A.; Frisbee, J.C. Cerebral Cortical Microvascular Rarefaction in Metabolic Syndrome is Dependent on Insulin Resistance and Loss of Nitric Oxide Bioavailability. Microcirculation 2015, 22((6)), 435–445. [Google Scholar] [CrossRef]
- Gosalia, J.; Delgado Spicuzza, J.M.; Bowlus, C.K.; Gardner, A.W.; Dennis, N.A.; Pawelczyk, J.A.; Proctor, D.N. Impaired neurovascular coupling in metabolic syndrome: an fNIRS study. Journal of Applied Physiology 2025, 138((6)), 1651–1663. [Google Scholar] [CrossRef]
- Shi, F.-D.; Yong, V.W. Neuroinflammation across neurological diseases. Science 2025, 388((6753)), eadx0043. [Google Scholar] [CrossRef] [PubMed]
- Haeusler, R.A.; McGraw, T.E.; Accili, D. Biochemical and cellular properties of insulin receptor signalling. Nature Reviews Molecular Cell Biology 2018, 19((1)), 31–44. [Google Scholar] [CrossRef]
- Batista, T.M.; Cederquist, C.T.; Kahn, C.R. The insulin receptor goes nuclear. Cell Research 2019, 29((7)), 509–511. [Google Scholar] [CrossRef]
- Frasca, F.; Pandini, G.; Scalia, P.; Sciacca, L.; Mineo, R.; Costantino, A.; Goldfine, I.D.; Belfiore, A.; Vigneri, R. Insulin Receptor Isoform A, a Newly Recognized, High-Affinity Insulin-Like Growth Factor II Receptor in Fetal and Cancer Cells. Molecular and Cellular Biology 1999, 19((5)), 3278–3288. [Google Scholar] [CrossRef]
- Choi, E.; Bai, X.-C. The Activation Mechanism of the Insulin Receptor: A Structural Perspective. Annual Review of Biochemistry 2023, 92((Volume 92, 2023)), 247–272. [Google Scholar] [CrossRef]
- Stange, A.D.; Zuzic, L.; Schiøtt, B.; Berglund, N.A. Exploring insulin-receptor dynamics: Stability and binding mechanisms. Structure 2025, 33((8)), 1425–1435.e2. [Google Scholar] [CrossRef]
- Tsuchiya, K.; Ogawa, Y. Forkhead box class O family member proteins: The biology and pathophysiological roles in diabetes. Journal of Diabetes Investigation 2017, 8((6)), 726–734. [Google Scholar] [CrossRef]
- Gao, X.; Pan, D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 2001, 15((11)), 1383–1392. [Google Scholar] [CrossRef] [PubMed]
- Saltiel, A.R. Insulin signaling in health and disease. The Journal of Clinical Investigation 2021, 131((1)). [Google Scholar] [CrossRef]
- Wang, L.; Li, J.; Di, L.-j. Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases. Medicinal Research Reviews 2022, 42((2)), 946–982. [Google Scholar] [CrossRef]
- Lizcano, J.M.; Alessi, D.R. The insulin signalling pathway. Current Biology 2002, 12((7)), R236–R238. [Google Scholar] [CrossRef]
- Springer, C.; Binsch, C.; Weide, D.; Toska, L.; Cremer, A.L.; Backes, H.; Scheel, A.K.; Espelage, L.; Kotzka, J.; Sill, S.; Kurowski, A.; Kim, D.; Karpinski, S.; Schnurr, T.M.; Hansen, T.; Hartwig, S.; Lehr, S.; Cames, S.; Brüning, J.C.; Lienhard, M.; Herwig, R.; Börno, S.; Timmermann, B.; Al-Hasani, H.; Chadt, A. Depletion of TBC1D4 Improves the Metabolic Exercise Response by Overcoming Genetically Induced Peripheral Insulin Resistance. Diabetes 2024, 73((7)), 1058–1071. [Google Scholar] [CrossRef] [PubMed]
- Larsen, J.K.; Larsen, M.R.; Birk, J.B.; Steenberg, D.E.; Hingst, J.R.; Højlund, K.; Chadt, A.; Al-Hasani, H.; Deshmukh, A.S.; Wojtaszewski, J.F.P.; Kjøbsted, R. Illumination of the Endogenous Insulin-Regulated TBC1D4 Interactome in Human Skeletal Muscle. Diabetes 2022, 71((5)), 906–920. [Google Scholar] [CrossRef] [PubMed]
- Lytrivi, M.; Tong, Y.; Virgilio, E.; Yi, X.; Cnop, M. Diabetes mellitus and the key role of endoplasmic reticulum stress in pancreatic β cells. Nature Reviews Endocrinology 2025, 21((9)), 546–563. [Google Scholar] [CrossRef]
- Li, M.; Chi, X.; Wang, Y.; Setrerrahmane, S.; Xie, W.; Xu, H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduction and Targeted Therapy 2022, 7((1)), 216. [Google Scholar] [CrossRef]
- Yaribeygi, H.; Sathyapalan, T.; Atkin, S.L.; Sahebkar, A. Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus. Oxid Med Cell Longev 2020, 2020, 8609213. [Google Scholar] [CrossRef] [PubMed]
- de Luca, C.; Olefsky, J.M. Inflammation and insulin resistance. FEBS Letters 2008, 582((1)), 97–105. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.-a.; Wei, Y.; Sowers, J.R. Role of Mitochondrial Dysfunction in Insulin Resistance. Circulation Research 2008, 102((4)), 401–414. [Google Scholar] [CrossRef]
- Iheagwam, F.N.; Joseph, A.J.; Adedoyin, E.D.; Iheagwam, O.T.; Ejoh, S.A. Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight. Pathophysiology 2025, 32((1)), 9. [Google Scholar] [CrossRef]
- Huang, L.-Y.; Liu, C.-H.; Chen, F.-Y.; Kuo, C.-H.; Pitrone, P.; Liu, J.-S. Aging Affects Insulin Resistance, Insulin Secretion, and Glucose Effectiveness in Subjects with Normal Blood Glucose and Body Weight. Diagnostics 2023, 13((13)), 2158. [Google Scholar] [CrossRef]
- NAITO, H.; KAGA, H.; KOGAI, T.; TAJIMA, T.; TABATA, H.; KAKEHI, S.; KADOWAKI, S.; WATADA, H.; TAMURA, Y. 1273-P: Five-Year Changes in Glucose Tolerance, Insulin Secretion, and Insulin Resistance in Community-Dwelling Older Adults. Diabetes (Supplement_1). 2025, 74. [Google Scholar] [CrossRef]
- Santoro, A.; McGraw, T.E.; Kahn, B.B. Insulin action in adipocytes, adipose remodeling, and systemic effects. Cell Metabolism 2021, 33((4)), 748–757. [Google Scholar] [CrossRef]
- Peterseim, C.M.; Jabbour, K.; Kamath Mulki, A. Metabolic Syndrome: An Updated Review on Diagnosis and Treatment for Primary Care Clinicians. J Prim Care Community Health 2024, 15, 21501319241309168. [Google Scholar] [CrossRef]
- Ginsberg, H.N. Insulin resistance and cardiovascular disease. J Clin Invest 2000, 106((4)), 453–458. [Google Scholar] [CrossRef]
- Zhou, M.S.; Wang, A.; Yu, H. Link between insulin resistance and hypertension: What is the evidence from evolutionary biology? Diabetol Metab Syndr 2014, 6((1)), 12. [Google Scholar] [CrossRef]
- Lal, R.M.; Golubic, R.; Ray, S. 18 The heterogeneity of obesity: a cross-sectional analysis of the UK biobank cohort. BMJ Nutrition, Prevention & Health 2025, 8 (Suppl 2). [Google Scholar]
- Clinically useful obesity subtypes revealed by harnessing deviations from population-average risk. Nature Medicine 2025, 31((2)), 392–393. [CrossRef]
- Obesity and overweight | World Health Organization (WHO). Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed on 8 December 2025).
- DeFronzo, R.A.; Tripathy, D. Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes. Diabetes Care 2009, 32, S157–S163. [Google Scholar] [CrossRef] [PubMed]
- Kawaguchi, T.; Taniguchi, E.; Itou, M.; Sakata, M.; Sumie, S.; Sata, M. Insulin resistance and chronic liver disease. World J Hepatol 2011, 3((5)), 99–107. [Google Scholar] [CrossRef]
- Olivares-Vicente, M.; Herranz-López, M. The Interplay Between Oxidative Stress and Lipid Composition in Obesity-Induced Inflammation: Antioxidants as Therapeutic Agents in Metabolic Diseases. International Journal of Molecular Sciences 2025, 26((17)), 8544. [Google Scholar] [CrossRef]
- Medina-Leyte, D.J.; Zepeda-García, O.; Domínguez-Pérez, M.; González-Garrido, A.; Villarreal-Molina, T.; Jacobo-Albavera, L. Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. International Journal of Molecular Sciences 2021, 22((8)), 3850. [Google Scholar] [CrossRef]
- Dobre, M.-Z.; Virgolici, B.; Dunca-Stefan, D.C.A.; Doicin, I.-C.; Stanescu-Spinu, I.-I. Inflammation—Insulin Resistance Crosstalk and the Central Role of Myokines. International Journal of Molecular Sciences 2026, 27((1)), 60. [Google Scholar] [CrossRef]
- Deng, Q.; Kang, H.; Cao, Y.; Tian, R.; Chen, D.; Yu, H.; Zhu, J.; He, Y.; Zhang, J.; Liu, X.; Sheng, J.; Wang, S. Mediating Role of Insulin Resistance in the Association Between Body Composition and Hypertension. High Blood Pressure & Cardiovascular Prevention 2025. [Google Scholar]
- Ryan, A.J.; Ciaraldi, T.P.; Henry, R.R. Myokine Regulation of Insulin Secretion: Impact of Inflammation and Type 2 Diabetes. Front Physiol 2019, 10, 1608. [Google Scholar] [CrossRef]
- Iglesias, P. Muscle in Endocrinology: From Skeletal Muscle Hormone Regulation to Myokine Secretion and Its Implications in Endocrine-Metabolic Diseases. J Clin Med 2025, 14, 13. [Google Scholar] [CrossRef] [PubMed]
- Yi, J.; Chen, J.; Yao, X.; Zhao, Z.; Niu, X.; Li, X.; Sun, J.; Ji, Y.; Shang, T.; Gong, L.; Chen, B.; Sun, H. Myokine-mediated muscle-organ interactions: Molecular mechanisms and clinical significance. Biochemical Pharmacology 2025, 242, 117326. [Google Scholar] [CrossRef] [PubMed]
- Jalil, Y.; Damiani, L.F.; García-Valdés, P.; Basoalto, R.; Gallastegui, J.; Gutierrez-Arias, R. Myokine Secretion Dynamics and Their Role in Critically Ill Patients: A Scoping Review. J Clin Med 2025, 14((9)). [Google Scholar] [CrossRef] [PubMed]
- Ozaki, Y.; Ohashi, K.; Otaka, N.; Kawanishi, H.; Takikawa, T.; Fang, L.; Takahara, K.; Tatsumi, M.; Ishihama, S.; Takefuji, M.; Kato, K.; Shimizu, Y.; Bando, Y.K.; Inoue, A.; Kuzuya, M.; Miura, S.; Murohara, T.; Ouchi, N. Myonectin protects against skeletal muscle dysfunction in male mice through activation of AMPK/PGC1α pathway. Nature Communications 2023, 14((1)), 4675. [Google Scholar] [CrossRef]
- Noubiap, J.J.; Nansseu, J.R.; Nyaga, U.F.; Ndoadoumgue, A.L.; Ngouo, A.T.; Tounouga, D.N.; Tianyi, F.-L.; Foka, A.J.; Lontchi-Yimagou, E.; Nkeck, J.R.; Bigna, J.J. Worldwide trends in metabolic syndrome from 2000 to 2023: a systematic review and modelling analysis. Nature Communications 2025. [Google Scholar] [CrossRef]
- Xue, M.; Xu, W.; Ou, Y.-N.; Cao, X.-P.; Tan, M.-S.; Tan, L.; Yu, J.-T. Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies. Ageing Research Reviews 2019, 55, 100944. [Google Scholar] [CrossRef]
- Brouwers, B.; Schrauwen-Hinderling, Vera B.; Jelenik, T.; Gemmink, A.; Havekes, B.; Bruls, Y.; Dahlmans, D.; Roden, M.; Hesselink, Matthijs K. C.; Schrauwen, P. Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes. Clinical Science 2017, 131((15)), 1905–1917. [Google Scholar] [CrossRef]
- Kolterman, O.G.; Gray, R.S.; Griffin, J.; Burstein, P.; Insel, J.; Scarlett, J.A.; Olefsky, J.M. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. The Journal of Clinical Investigation 1981, 68((4)), 957–969. [Google Scholar] [CrossRef]
- Prasad, A.; Quyyumi, A.A. Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome. Circulation 2004, 110((11)), 1507–1512. [Google Scholar] [CrossRef]
- Gonzalez, A.B. d.; Hartge, P.; Cerhan, J.R.; Flint, A.J.; Hannan, L.; MacInnis, R.J.; Moore, S.C.; Tobias, G.S.; Anton-Culver, H.; Freeman, L.B.; Beeson, W.L.; Clipp, S.L.; English, D.R.; Folsom, A.R.; Freedman, D.M.; Giles, G.; Hakansson, N.; Henderson, K.D.; Hoffman-Bolton, J.; Hoppin, J.A.; Koenig, K.L.; Lee, I.-M.; Linet, M.S.; Park, Y.; Pocobelli, G.; Schatzkin, A.; Sesso, H.D.; Weiderpass, E.; Willcox, B.J.; Wolk, A.; Zeleniuch-Jacquotte, A.; Willett, W.C.; Thun, M.J. Body-Mass Index and Mortality among 1.46 Million White Adults. New England Journal of Medicine 2010, 363((23)), 2211–2219. [Google Scholar] [CrossRef]
- Bouchard, C.; Tremblay, A.; Després, J.-P.; Nadeau, A.; Lupien, P.J.; Thériault, G.; Dussault, J.; Moorjani, S.; Pinault, S.; Fournier, G. The Response to Long-Term Overfeeding in Identical Twins. New England Journal of Medicine 1990, 322((21)), 1477–1482. [Google Scholar] [CrossRef] [PubMed]
- Yu, J.H.; Baik, I.; Cho, H.J.; Seo, J.A.; Kim, S.G.; Choi, K.M.; Baik, S.H.; Choi, D.S.; Shin, C.; Kim, N.H. The FTO rs9939609 polymorphism is associated with short leukocyte telomere length in nonobese individuals. Medicine (Baltimore) 2017, 96((30)), e7565. [Google Scholar] [CrossRef]
- Tchernof, A.; Després, J.-P. Pathophysiology of Human Visceral Obesity: An Update. Physiological Reviews 2013, 93((1)), 359–404. [Google Scholar] [CrossRef] [PubMed]
- Hetemäki, N.; Savolainen-Peltonen, H.; Tikkanen, M.J.; Wang, F.; Paatela, H.; Hämäläinen, E.; Turpeinen, U.; Haanpää, M.; Vihma, V.; Mikkola, T.S. Estrogen Metabolism in Abdominal Subcutaneous and Visceral Adipose Tissue in Postmenopausal Women. J Clin Endocrinol Metab 2017, 102((12)), 4588–4595. [Google Scholar] [CrossRef]
- Su, M.; Wei, H.; Chen, L.; Guan, Y.; Dong, W.; Zhao, M. The Impact of Visceral Adiposity on Testosterone Levels in American Adult Men: A Cross-Sectional Analysis. Med Sci Monit 2023, 29, e941394. [Google Scholar] [CrossRef]
- Janssen, I.; Powell, L.H.; Kazlauskaite, R.; Dugan, S.A. Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study. Obesity (Silver Spring) 2010, 18((3)), 604–610. [Google Scholar] [CrossRef]
- Karelis, A.D.; St-Pierre, D.H.; Conus, F.; Rabasa-Lhoret, R.; Poehlman, E.T. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab 2004, 89((6)), 2569–2575. [Google Scholar] [CrossRef]
- Camhi, S.M.; Must, A.; Gona, P.N.; Hankinson, A.; Odegaard, A.; Reis, J.; Gunderson, E.P.; Jacobs, D.R.; Carnethon, M.R. Duration and stability of metabolically healthy obesity over 30 years. Int J Obes (Lond) 2019, 43((9)), 1803–1810. [Google Scholar] [CrossRef]
- Wildman, R.P.; Muntner, P.; Reynolds, K.; McGinn, A.P.; Rajpathak, S.; Wylie-Rosett, J.; Sowers, M.R. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008, 168((15)), 1617–1624. [Google Scholar] [CrossRef]
- Després, J.-P. Body Fat Distribution and Risk of Cardiovascular Disease. Circulation 2012, 126((10)), 1301–1313. [Google Scholar] [CrossRef] [PubMed]
- Lavie, C.J.; Milani, R.V.; Ventura, H.O. Obesity and Cardiovascular Disease. JACC 2009, 53((21)), 1925–1932. [Google Scholar] [CrossRef] [PubMed]
- Goff, D.C.; Lloyd-Jones, D.M.; Bennett, G.; Coady, S.; D’Agostino, R.B.; Gibbons, R.; Greenland, P.; Lackland, D.T.; Levy, D.; O’Donnell, C.J.; Robinson, J.G.; Schwartz, J.S.; Shero, S.T.; Smith, S.C.; Sorlie, P.; Stone, N.J. Wilson, P.W.F., 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation 2014, 129((25_) suppl_2, S49–S73. [Google Scholar] [CrossRef]
- National Health and Nutrition Examination Survey 2017–March 2020 prepandemic data files development of files and prevalence estimates for selected health outcomes. Natl Health Stat Report. 2021; p. 158. Available online: https://stacks.cdc.gov/view/cdc/106273 (accessed on 15 January 2026).
- Neeland, I.J.; Poirier, P.; Després, J.-P. Cardiovascular and Metabolic Heterogeneity of Obesity. Circulation 2018, 137((13)), 1391–1406. [Google Scholar] [CrossRef]
- Sahakyan, K.R.; Somers, V.K.; Rodriguez-Escudero, J.P.; Hodge, D.O.; Carter, R.E.; Sochor, O.; Coutinho, T.; Jensen, M.D.; Roger, V.L.; Singh, P.; Lopez-Jimenez, F. Normal-Weight Central Obesity: Implications for Total and Cardiovascular Mortality. Ann Intern Med 2015, 163((11)), 827–835. [Google Scholar] [CrossRef]
- Vesković, M.; Šutulović, N.; Hrnčić, D.; Stanojlović, O.; Macut, D.; Mladenović, D. The Interconnection between Hepatic Insulin Resistance and Metabolic Dysfunction-Associated Steatotic Liver Disease—The Transition from an Adipocentric to Liver-Centric Approach. Current Issues in Molecular Biology 2023, 45((11)), 9084–9102. [Google Scholar] [CrossRef] [PubMed]
- Lee, K.J.; Kim, M.Y.; Han, Y.H. Roles of heterogenous hepatic macrophages in the progression of liver diseases. BMB Rep 2022, 55((4)), 166–174. [Google Scholar] [CrossRef] [PubMed]
- Nusse, Y.; Kubes, P. Liver macrophages: development, dynamics, and functions. Cellular & Molecular Immunology 2025, 22((10)), 1178–1189. [Google Scholar] [CrossRef] [PubMed]
- Li, H.; You, H.; Fan, X.; Jia, J. Hepatic macrophages in liver fibrosis: pathogenesis and potential therapeutic targets. BMJ Open Gastroenterol 2016, 3((1)), e000079. [Google Scholar] [CrossRef]
- Wen, Y.; Lambrecht, J.; Ju, C.; Tacke, F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cellular & Molecular Immunology 2021, 18((1)), 45–56. [Google Scholar]
- Tantu, M.T.; Farhana, F.Z.; Haque, F.; Koo, K.M.; Qiao, L.; Ross, A.G.; Shiddiky, M.J.A. Pathophysiology, noninvasive diagnostics and emerging personalized treatments for metabolic associated liver diseases. npj Gut and Liver 2025, 2((1)), 18. [Google Scholar] [CrossRef]
- Yanai, H.; Adachi, H.; Hakoshima, M.; Iida, S.; Katsuyama, H. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. Int J Mol Sci 2023, 24, 20. [Google Scholar] [CrossRef]
- Schmidt-Christensen, A.; Eriksson, G.; Laprade, W.M.; Pirzamanbein, B.; Hörnberg, M.; Linde, K.; Nilsson, J.; Skarsfeldt, M.; Leeming, D.J.; Mokso, R.; Verezhak, M.; Dahl, A.; Dahl, V.; Önnerhag, K.; Oghazi, M.R.; Mayans, S.; Holmberg, D. Structure-function analysis of time-resolved immunological phases in metabolic dysfunction-associated fatty liver disease (MASH) comparing the NIF mouse model to human MASH. Scientific Reports 2024, 14((1)), 23014. [Google Scholar] [CrossRef]
- Younossi, Z.M.; Golabi, P.; de Avila, L.; Paik, J.M.; Srishord, M.; Fukui, N.; Qiu, Y.; Burns, L.; Afendy, A.; Nader, F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. Journal of Hepatology 2019, 71((4)), 793–801. [Google Scholar] [CrossRef]
- Chen, Y.; Bian, S.; Le, J. Molecular Landscape and Diagnostic Model of MASH: Transcriptomic, Proteomic, Metabolomic, and Lipidomic Perspectives. Genes (Basel) 2025, 16((4)). [Google Scholar] [CrossRef]
- Wang, Z.; Cao, Z.; Dong, Y.; Hong, Y.; Zuo, L.; Wang, H. Hepatocyte-hepatic stellate cell interactions in liver fibrosis: Mechanisms and therapeutic implications. Hepatol Commun 2026, 10((2)). [Google Scholar] [CrossRef] [PubMed]
- Yanai, H.; Adachi, H.; Hakoshima, M.; Iida, S.; Katsuyama, H. Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. International Journal of Molecular Sciences 2023, 24((20)), 15473. [Google Scholar] [CrossRef]
- Chekol Abebe, E.; Tilahun Muche, Z.; Behaile, T.M.A.; Mengie Ayele, T.; Mekonnen Agidew, M.; Teshome Azezew, M.; Abebe Zewde, E.; Asmamaw Dejenie, T.; Asmamaw Mengstie, M. The structure, biosynthesis, and biological roles of fetuin-A: A review. Front Cell Dev Biol 2022, 10, 945287. [Google Scholar] [CrossRef] [PubMed]
- Mukhopadhyay, S.; Mondal, S.A.; Kumar, M.; Dutta, D. Proinflammatory and Antiinflammatory Attributes of Fetu Iν-A: A Novel Hepatokine Modulating Cardiovascular and Glycemic Outcomes in Metabolic Syndrome. Endocrine Practice 2014, 20((12)), 1345–1351. [Google Scholar] [CrossRef] [PubMed]
- Rudloff, S.; Janot, M.; Rodriguez, S.; Dessalle, K.; Jahnen-Dechent, W.; Huynh-Do, U. Fetuin-A is a HIF target that safeguards tissue integrity during hypoxic stress. Nature Communications 2021, 12((1)), 549. [Google Scholar] [CrossRef]
- Nobs, S.P.; Kopf, M. Tissue-resident macrophages: guardians of organ homeostasis. Trends in Immunology 2021, 42((6)), 495–507. [Google Scholar] [CrossRef]
- Strizova, Z.; Benesova, I.; Bartolini, R.; Novysedlak, R.; Cecrdlova, E.; Foley, L.K.; Striz, I. M1/M2 macrophages and their overlaps - myth or reality? Clin Sci (Lond) 2023, 137((15)), 1067–1093. [Google Scholar] [CrossRef]
- Nawaz, A.; Aminuddin, A.; Kado, T.; Takikawa, A.; Yamamoto, S.; Tsuneyama, K.; Igarashi, Y.; Ikutani, M.; Nishida, Y.; Nagai, Y.; Takatsu, K.; Imura, J.; Sasahara, M.; Okazaki, Y.; Ueki, K.; Okamura, T.; Tokuyama, K.; Ando, A.; Matsumoto, M.; Mori, H.; Nakagawa, T.; Kobayashi, N.; Saeki, K.; Usui, I.; Fujisaka, S.; Tobe, K. CD206(+) M2-like macrophages regulate systemic glucose metabolism by inhibiting proliferation of adipocyte progenitors. Nat Commun 2017, 8((1)), 286. [Google Scholar] [CrossRef] [PubMed]
- Mouton, A.J.; Li, X.; Hall, M.E.; Hall, J.E. Obesity, Hypertension, and Cardiac Dysfunction. Circulation Research 2020, 126((6)), 789–806. [Google Scholar] [CrossRef]
- Arslanian, S.; Suprasongsin, C. Differences in the in vivo insulin secretion and sensitivity of healthy black versus white adolescents. The Journal of Pediatrics 1996, 129((3)), 440–443. [Google Scholar] [CrossRef] [PubMed]
- Ogawa, W. Insulin resistance and adipose tissue. Diabetol Int 2023, 14((2)), 117–118. [Google Scholar] [CrossRef]
- Miao, Z.; Alvarez, M.; Ko, A.; Bhagat, Y.; Rahmani, E.; Jew, B.; Heinonen, S.; Muñoz-Hernandez, L.L.; Herrera-Hernandez, M.; Aguilar-Salinas, C.; Tusie-Luna, T.; Mohlke, K.L.; Laakso, M.; Pietiläinen, K.H.; Halperin, E.; Pajukanta, P. The causal effect of obesity on prediabetes and insulin resistance reveals the important role of adipose tissue in insulin resistance. PLoS Genet 2020, 16((9)), e1009018. [Google Scholar] [CrossRef]
- Cignarelli, A.; Genchi, V.A.; Perrini, S.; Natalicchio, A.; Laviola, L.; Giorgino, F. Insulin and Insulin Receptors in Adipose Tissue Development. Int J Mol Sci 2019, 20((3)). [Google Scholar] [CrossRef]
- Meredith-Jones, K.; Taylor, R.; Brown, R.; Cooke, R.; Vlietstra, L.; Manning, P.; Poulton, R.; Haszard, J. Age- and sex-specific visceral fat reference cutoffs and their association with cardio-metabolic risk. International Journal of Obesity 2021, 45((4)), 808–817. [Google Scholar] [CrossRef]
- Goran, M.I.; Nagy, T.R.; Treuth, M.S.; Trowbridge, C.; Dezenberg, C.; McGloin, A.; Gower, B.A. Visceral fat in white and African American prepubertal children. The American Journal of Clinical Nutrition 1997, 65((6)), 1703–1708. [Google Scholar] [CrossRef] [PubMed]
- Carroll, J.F.; Chiapa, A.L.; Rodriquez, M.; Phelps, D.R.; Cardarelli, K.M.; Vishwanatha, J.K.; Bae, S.; Cardarelli, R. Visceral Fat, Waist Circumference, and BMI: Impact of Race/ethnicity. Obesity 2008, 16((3)), 600–607. [Google Scholar] [CrossRef]
- Osei, K.; Schuster, D.P. Ethnic Differences in Secretion, Sensitivity, and Hepatic Extraction of Insulin in Black and White Americans. Diabetic Medicine 1994, 11((8)), 755–762. [Google Scholar] [CrossRef]
- Chilunga, F.P.; Meeks, K.A.C.; Henneman, P.; Agyemang, C.; Doumatey, A.P.; Rotimi, C.N.; Adeyemo, A.A. An epigenome-wide association study of insulin resistance in African Americans. Clin Epigenetics 2022, 14((1)), 88. [Google Scholar] [CrossRef] [PubMed]
- Petersen, K.F.; Dufour, S.; Savage, D.B.; Bilz, S.; Solomon, G.; Yonemitsu, S.; Cline, G.W.; Befroy, D.; Zemany, L.; Kahn, B.B.; Papademetris, X.; Rothman, D.L.; Shulman, G.I. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proceedings of the National Academy of Sciences 2007, 104((31)), 12587–12594. [Google Scholar] [CrossRef] [PubMed]
- Parcha, V.; Heindl, B.; Kalra, R.; Li, P.; Gower, B.; Arora, G.; Arora, P. Insulin Resistance and Cardiometabolic Risk Profile Among Nondiabetic American Young Adults: Insights From NHANES. J Clin Endocrinol Metab 2022, 107((1)), e25–e37. [Google Scholar] [CrossRef]
- Gonzalez-Cantero, J.; Martin-Rodriguez, J.L.; Gonzalez-Cantero, A.; Arrebola, J.P.; Gonzalez-Calvin, J.L. Insulin resistance in lean and overweight non-diabetic Caucasian adults: Study of its relationship with liver triglyceride content, waist circumference and BMI. PLOS ONE 2018, 13((2)), e0192663. [Google Scholar] [CrossRef]
- Curat, C.A.; Wegner, V.; Sengenès, C.; Miranville, A.; Tonus, C.; Busse, R.; Bouloumié, A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006, 49((4)), 744–747. [Google Scholar] [CrossRef] [PubMed]
- Wang, T.; Zhang, X.; Bheda, P.; Revollo, J.R.; Imai, S.-i.; Wolberger, C. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nature Structural & Molecular Biology 2006, 13((7)), 661–662. [Google Scholar]
- Revollo, J.R.; Körner, A.; Mills, K.F.; Satoh, A.; Wang, T.; Garten, A.; Dasgupta, B.; Sasaki, Y.; Wolberger, C.; Townsend, R.R.; Milbrandt, J.; Kiess, W.; Imai, S. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007, 6((5)), 363–375. [Google Scholar] [CrossRef]
- Alegre, G.F.S.; Pastore, G.M. NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health. Current Nutrition Reports 2023, 12((3)), 445–464. [Google Scholar] [CrossRef]
- Stastny, J.; Bienertova-Vasku, J.; Vasku, A. Visfatin and its role in obesity development. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2012, 6((2)), 120–124. [Google Scholar] [CrossRef]
- Takebayashi, K.; Suetsugu, M.; Wakabayashi, S.; Aso, Y.; Inukai, T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007, 56((4)), 451–458. [Google Scholar] [CrossRef]
- Romacho, T.; Valencia, I.; Ramos-González, M.; Vallejo, S.; López-Esteban, M.; Lorenzo, O.; Cannata, P.; Romero, A.; San Hipólito-Luengo, A.; Gómez-Cerezo, J.F.; Peiró, C.; Sánchez-Ferrer, C.F. Visfatin/eNampt induces endothelial dysfunction in vivo: a role for Toll-Like Receptor 4 and NLRP3 inflammasome. Scientific Reports 2020, 10((1)), 5386. [Google Scholar] [CrossRef]
- López-Bermejo, A.; Chico-Julià, B.; Fernàndez-Balsells, M.; Recasens, M. n.; Esteve, E.; Casamitjana, R.; Ricart, W.; Fernández-Real, J.-M. Serum Visfatin Increases With Progressive β-Cell Deterioration. Diabetes 2006, 55((10)), 2871–2875. [Google Scholar] [CrossRef]
- Skop, V.; Kontrová, K.; Zídek, V.; Pravenec, M.; Kazdová, L.; Mikulík, K.; Sajdok, J.; Zídková, J. Autocrine effects of visfatin on hepatocyte sensitivity to insulin action. Physiol Res 2010, 59((4)), 615–618. [Google Scholar] [CrossRef]
- Jarrar, M.H.; Baranova, A.; Collantes, R.; Ranard, B.; Stepanova, M.; Bennett, C.; Fang, Y.; Elariny, H.; Goodman, Z.; Chandhoke, V.; Younossi, Z.M. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008, 27((5)), 412–421. [Google Scholar] [CrossRef]
- Haider, D.G.; Schindler, K.; Schaller, G.; Prager, G.; Wolzt, M.; Ludvik, B. Increased Plasma Visfatin Concentrations in Morbidly Obese Subjects Are Reduced after Gastric Banding. The Journal of Clinical Endocrinology & Metabolism 2006, 91((4)), 1578–1581. [Google Scholar] [CrossRef] [PubMed]
- Chen, M.P.; Chung, F.M.; Chang, D.M.; Tsai, J.C.; Huang, H.F.; Shin, S.J.; Lee, Y.J. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006, 91((1)), 295–299. [Google Scholar] [CrossRef]
- Masood, S.H.; Khan, T.A.; Baloch, A.A.; Hasan, S.M.; Naqvi, A.M.; Iqbal, M. u. N. Association of Visfatin gene polymorphism with obesity related metabolic disorders among Pakistani population: a case control study. Scientific Reports 2023, 13((1)), 23002. [Google Scholar] [CrossRef] [PubMed]
- Rahmati, S.; Sadeghi, S.; Mahalleh, M.; Behnoush, A.H.; Pourgholi, M.; Hosseini, K.; Moosazadeh, M. Circulating levels of visfatin and apelin as biomarkers in chronic kidney disease: a systematic review and meta-analysis. International Urology and Nephrology 2025, 57((9)), 2901–2915. [Google Scholar] [CrossRef]
- Mori, K.; Emoto, M.; Araki, T.; Yokoyama, H.; Lee, E.; Teramura, M.; Koyama, H.; Shoji, T.; Inaba, M.; Nishizawa, Y. Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. Metabolism 2008, 57((9)), 1248–1252. [Google Scholar] [CrossRef] [PubMed]
- Lin, Y.-H.; Franc, V.; Heck, A.J.R. Similar Albeit Not the Same: In-Depth Analysis of Proteoforms of Human Serum, Bovine Serum, and Recombinant Human Fetuin. Journal of Proteome Research 2018, 17((8)), 2861–2869. [Google Scholar] [CrossRef]
- Mori, K.; Emoto, M.; Inaba, M. Fetuin-A: a multifunctional protein. Recent Pat Endocr Metab Immune Drug Discov 2011, 5((2)), 124–146. [Google Scholar] [CrossRef]
- Kovářová, M.; Kalbacher, H.; Peter, A.; Häring, H.-U.; Didangelos, T.; Stefan, N.; Birkenfeld, A.; Schleicher, E.; Kantartzis, K. Detection and Characterization of Phosphorylation, Glycosylation, and Fatty Acid Bound to Fetuin A in Human Blood. Journal of Clinical Medicine 2021, 10((3)), 411. [Google Scholar] [CrossRef]
- Cai, M.M.; Smith, E.R.; Holt, S.G. The role of fetuin-A in mineral trafficking and deposition. Bonekey Rep 2015, 4, 672. [Google Scholar] [CrossRef]
- Uedono, H.; Mori, K.; Ochi, A.; Nakatani, S.; Miki, Y.; Tsuda, A.; Morioka, T.; Nagata, Y.; Imanishi, Y.; Shoji, T.; Inaba, M.; Emoto, M. Effects of fetuin-A-containing calciprotein particles on posttranslational modifications of fetuin-A in HepG2 cells. Scientific Reports 2021, 11((1)), 7486. [Google Scholar] [CrossRef]
- Pal, D.; Dasgupta, S.; Kundu, R.; Maitra, S.; Das, G.; Mukhopadhyay, S.; Ray, S.; Majumdar, S.S.; Bhattacharya, S. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nature Medicine 2012, 18((8)), 1279–1285. [Google Scholar] [CrossRef] [PubMed]
- Weikert, C.; Stefan, N.; Schulze, M.B.; Pischon, T.; Berger, K.; Joost, H.-G.; Häring, H.-U.; Boeing, H.; Fritsche, A. Plasma Fetuin-A Levels and the Risk of Myocardial Infarction and Ischemic Stroke. Circulation 2008, 118((24)), 2555–2562. [Google Scholar] [CrossRef]
- Chatterjee, P.; Seal, S.; Mukherjee, S.; Kundu, R.; Mukherjee, S.; Ray, S.; Mukhopadhyay, S.; Majumdar, S.S.; Bhattacharya, S. Adipocyte Fetuin-A Contributes to Macrophage Migration into Adipose Tissue and Polarization of Macrophages*. Journal of Biological Chemistry 2013, 288((39)), 28324–28330. [Google Scholar] [CrossRef]
- Mukhuty, A.; Fouzder, C.; Kundu, R. Fetuin-A secretion from β-cells leads to accumulation of macrophages in islets, aggravates inflammation and impairs insulin secretion. Journal of Cell Science 2021, 134, 21. [Google Scholar] [CrossRef] [PubMed]
- Chatterjee, P.; Seal, S.; Mukherjee, S.; Kundu, R.; Mukherjee, S.; Ray, S.; Mukhopadhyay, S.; Majumdar, S.S.; Bhattacharya, S. Adipocyte Fetuin-A Contributes to Macrophage Migration into Adipose Tissue and Polarization of Macrophages *. Journal of Biological Chemistry 2013, 288((39)), 28324–28330. [Google Scholar] [CrossRef]
- Milani, I.; Codini, M.; Guarisco, G.; Chinucci, M.; Gaita, C.; Leonetti, F.; Capoccia, D. Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic Target. International Journal of Molecular Sciences 2024, 25((19)), 10795. [Google Scholar] [CrossRef] [PubMed]
- Sindhu, S.; Akhter, N.; Shenouda, S.; Wilson, A.; Ahmad, R. Plasma fetuin-A/α2-HS-glycoprotein correlates negatively with inflammatory cytokines, chemokines and activation biomarkers in individuals with type-2 diabetes. BMC Immunology 2016, 17((1)), 33. [Google Scholar] [CrossRef] [PubMed]
- Chekol Abebe, E.; Tilahun Muche, Z.; Behaile T/Mariam, A.; Mengie Ayele, T.; Mekonnen Agidew, M.; Teshome Azezew, M.; Abebe Zewde, E.; Asmamaw Dejenie, T.; Asmamaw Mengstie, M. The structure, biosynthesis, and biological roles of fetuin-A: A review. Frontiers in Cell and Developmental Biology 2022, 10–2022. [Google Scholar] [CrossRef] [PubMed]
- Jemal, M.; Waritu, N.C.; Baylie, T.; Sinamaw, D.; Mengistu, E.F.; Osman, E.E.; Baye, G.; Tegegne, B.A.; Amare, G.A.; Teffera, Z.H.; Malik, T.; Malede, B.; Ashenef, B.; Abebaw, D.; Adugna, A. The evolving roles of fetuin-A in type 2 diabetes mellitus and its potential clinical implications: a review. Therapeutic Advances in Chronic Disease 2025, 16, 20406223251389795. [Google Scholar] [CrossRef] [PubMed]
- Hida, K.; Wada, J.; Eguchi, J.; Zhang, H.; Baba, M.; Seida, A.; Hashimoto, I.; Okada, T.; Yasuhara, A.; Nakatsuka, A.; Shikata, K.; Hourai, S.; Futami, J.; Watanabe, E.; Matsuki, Y.; Hiramatsu, R.; Akagi, S.; Makino, H.; Kanwar, Y.S. Visceral adipose tissue-derived serine protease inhibitor: A unique insulin-sensitizing adipocytokine in obesity. Proceedings of the National Academy of Sciences 2005, 102((30)), 10610–10615. [Google Scholar] [CrossRef]
- Möhlis, K.; Useini, A.; Betat, H.; Bonin, S.; Broghammer, H.; Nuwayhid, R.; Langer, S.; Mörl, M.; Sträter, N.; Heiker, J.T. Vaspin identified as a DNA-binding serpin with functional consequences for protease inhibition. Febs j 2025. [Google Scholar] [CrossRef]
- Nicholson, T.; Church, C.; Tsintzas, K.; Jones, R.; Breen, L.; Davis, E.T.; Baker, D.J.; Jones, S.W. Vaspin promotes insulin sensitivity in elderly muscle and is upregulated in obesity. J Endocrinol 2019, 241((1)), 31–43. [Google Scholar] [CrossRef] [PubMed]
- Vehapoglu, A.; Ustabas, F.; Ozgen, T.I.; Terzioglu, S.; Cermik, B.B.; Ozen, O.F. Role of circulating adipocytokines vaspin, apelin, and visfatin in the loss of appetite in underweight children: a pilot trial. Journal of Pediatric Endocrinology and Metabolism 2015, 28((9-10)), 1065–1071. [Google Scholar] [CrossRef] [PubMed]
- Breitfeld, J.; Heiker, J.T.; Böttcher, Y.; Schleinitz, D.; Tönjes, A.; Weidle, K.; Krause, K.; Kuettner, E.B.; Scholz, M.; Kiess, W. Analysis of a rare functional truncating mutation rs61757459 in vaspin (SERPINA12) on circulating vaspin levels. Journal of Molecular Medicine 2013, 91((11)), 1285–1292. [Google Scholar] [CrossRef]
- Teshigawara, S.; Wada, J.; Hida, K.; Nakatsuka, A.; Eguchi, J.; Murakami, K.; Kanzaki, M.; Inoue, K.; Terami, T.; Katayama, A.; Iseda, I.; Matsushita, Y.; Miyatake, N.; McDonald, J.F.; Hotta, K.; Makino, H. Serum Vaspin Concentrations Are Closely Related to Insulin Resistance, and rs77060950 at SERPINA12 Genetically Defines Distinct Group with Higher Serum Levels in Japanese Population. The Journal of Clinical Endocrinology & Metabolism 2012, 97((7)), E1202–E1207. [Google Scholar]
- Kurowska, P.; Mlyczyńska, E.; Dawid, M.; Jurek, M.; Klimczyk, D.; Dupont, J.; Rak, A. Review: Vaspin (SERPINA12) Expression and Function in Endocrine Cells. Cells 2021, 10((7)), 1710. [Google Scholar] [CrossRef]
- de Oliveira dos Santos, A.R.; de Oliveira Zanuso, B.; Miola, V.F.B.; Barbalho, S.M.; Santos Bueno, P.C.; Flato, U.A.P.; Detregiachi, C.R.P.; Buchaim, D.V.; Buchaim, R.L.; Tofano, R.J.; Mendes, C.G.; Tofano, V.A.C.; dos Santos Haber, J.F. Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions. International Journal of Molecular Sciences 2021, 22((5)), 2639. [Google Scholar] [CrossRef]
- Merz, K.E.; Thurmond, D.C. Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake. Comprehensive Physiology 2020, 10((3)), 785–809. [Google Scholar] [CrossRef] [PubMed]
- Whytock, K.L.; Goodpaster, B.H. Unraveling Skeletal Muscle Insulin Resistance: Molecular Mechanisms and the Restorative Role of Exercise. Circulation Research 2025, 137((2)), 184–204. [Google Scholar] [CrossRef] [PubMed]
- Parikh, H.M.; Elgzyri, T.; Alibegovic, A.; Hiscock, N.; Ekström, O.; Eriksson, K.-F.; Vaag, A.; Groop, L.C.; Ström, K.; Hansson, O. Relationship between insulin sensitivity and gene expression in human skeletal muscle. BMC Endocrine Disorders 2021, 21((1)), 32. [Google Scholar] [CrossRef]
- Hashimoto, S.; Kubota, N.; Sato, H.; Sasaki, M.; Takamoto, I.; Kubota, T.; Nakaya, K.; Noda, M.; Ueki, K.; Kadowaki, T. Insulin Receptor Substrate-2 (Irs2) in Endothelial Cells Plays a Crucial Role in Insulin Secretion. Diabetes 2014, 64((3)), 876–886. [Google Scholar] [CrossRef]
- DeFronzo, R.A.; Jacot, E.; Jequier, E.; Maeder, E.; Wahren, J.; Felber, J.P. The Effect of Insulin on the Disposal of Intravenous Glucose: Results from Indirect Calorimetry and Hepatic and Femoral Venous Catheterization. Diabetes 1981, 30((12)), 1000–1007. [Google Scholar] [CrossRef]
- Sylow, L.; Tokarz, V.L.; Richter, E.A.; Klip, A. The many actions of insulin in skeletal muscle, the paramount tissue determining glycemia. Cell Metabolism 2021, 33((4)), 758–780. [Google Scholar] [CrossRef]
- Rustenbeck, I. Desensitization of insulin secretion. Biochemical Pharmacology 2002, 63((11)), 1921–1935. [Google Scholar] [CrossRef]
- Castillo, Í.M. P.; Argilés, J.M.; Rueda, R.; Ramírez, M.; Pedrosa, J.M.L. Skeletal muscle atrophy and dysfunction in obesity and type-2 diabetes mellitus: Myocellular mechanisms involved. Reviews in Endocrine and Metabolic Disorders 2025, 26((5)), 815–836. [Google Scholar] [CrossRef]
- Kjærgaard, J.; Stocks, B.; Henderson, J.; Freemantle, J.B.; Rizo-Roca, D.; Puglia, M.; Madrazo Montoya, M.; Andersson, D.; Bäckdahl, J.; Eriksson-Hogling, D.; Stidsen, J.V.; Wierer, M.; Rasmussen, S.; Sakamoto, K.; Højlund, K.; Rydén, M.; Zierath, J.R.; Krook, A.; Deshmukh, A.S. Personalized molecular signatures of insulin resistance and type 2 diabetes. Cell 2025, 188((15)), 4106–4122.e16. [Google Scholar] [CrossRef]
- Levate, G.; Stimson, R.H. Molecular signatures of skeletal muscle insulin resistance: bringing personalised diabetes treatment a step closer. Signal Transduction and Targeted Therapy 2025, 10((1)), 320. [Google Scholar] [CrossRef]
- Seko, T.; Himuro, N.; Koyama, M.; Nakata, K.; Akasaka, H.; Mori, M.; Ogawa, S.; Miura, S.; Ohnishi, H. Low skeletal muscle mass independently predicts the progression of insulin resistance in non-obese older adults: a six-year cohort study. Diabetology International 2025, 16((4)), 726–734. [Google Scholar] [CrossRef] [PubMed]
- DeFronzo, R.A.; Gunnarsson, R.; Björkman, O.; Olsson, M.; Wahren, J. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. The Journal of Clinical Investigation 1985, 76((1)), 149–155. [Google Scholar] [CrossRef]
- Steensberg, A.; van Hall, G.; Osada, T.; Sacchetti, M.; Saltin, B.; Klarlund Pedersen, B. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 2000, 529 Pt 1 (Pt 1), 237–42. [Google Scholar] [CrossRef]
- Kistner, T.M.; Pedersen, B.K.; Lieberman, D.E. Interleukin 6 as an energy allocator in muscle tissue. Nature Metabolism 2022, 4((2)), 170–179. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Xie, C.; Wang, H.; Foss, R.M.; Clare, M.; George, E.V.; Li, S.; Katz, A.; Cheng, H.; Ding, Y.; Tang, D.; Reeves, W.H.; Yang, L.-J. Irisin exerts dual effects on browning and adipogenesis of human white adipocytes. American Journal of Physiology-Endocrinology and Metabolism 2016, 311((2)), E530–E541. [Google Scholar] [CrossRef]
- Zhang, Y.; Li, R.; Meng, Y.; Li, S.; Donelan, W.; Zhao, Y.; Qi, L.; Zhang, M.; Wang, X.; Cui, T.; Yang, L.-J.; Tang, D. Irisin Stimulates Browning of White Adipocytes Through Mitogen-Activated Protein Kinase p38 MAP Kinase and ERK MAP Kinase Signaling. Diabetes 2014, 63((2)), 514–525. [Google Scholar] [CrossRef] [PubMed]
- Di Maio, G.; Alessio, N.; Ambrosino, A.; Al Sammarraie, S.H.A.; Monda, M.; Di Bernardo, G. Irisin influences the in vitro differentiation of human mesenchymal stromal cells, promoting a tendency toward beiging adipogenesis. J Cell Biochem 2024, 125((5)), e30565. [Google Scholar] [CrossRef]
- Ma, E.B.; Sahar, N.E.; Jeong, M.; Huh, J.Y. Irisin Exerts Inhibitory Effect on Adipogenesis Through Regulation of Wnt Signaling. Front Physiol 2019, 10, 1085. [Google Scholar] [CrossRef]
- Paoletti, I.; Coccurello, R. Irisin: A Multifaceted Hormone Bridging Exercise and Disease Pathophysiology. International Journal of Molecular Sciences 2024, 25((24)), 13480. [Google Scholar] [CrossRef]
- Mitroi Sakizlian, D.D.; Boldeanu, L.; Clenciu, D.; Mitrea, A.; Vladu, I.M.; Ciobanu Plasiciuc, A.E.; Assani, M.Z.; Ciobanu, D. Association of Circulating Irisin with Insulin Resistance and Metabolic Risk Markers in Prediabetic and Newly Diagnosed Type 2 Diabetes Patients. Int J Mol Sci 2026, 27((2)). [Google Scholar] [CrossRef]
- Toyoshima, Y.; Nakamura, K.; Taguchi, Y.; Tokita, R.; Takeuchi, S.; Osawa, H.; Teramoto, N.; Sugihara, H.; Yoshizawa, F.; Yamanouchi, K.; Minami, S. Deletion of IRS-1 leads to growth failure and insulin resistance with downregulation of liver and muscle insulin signaling in rats. Scientific Reports 2025, 15((1)), 649. [Google Scholar] [CrossRef]
- Piché, M.E.; Tardif, I.; Auclair, A.; Poirier, P. Effects of bariatric surgery on lipid-lipoprotein profile. Metabolism 2021, 115, 154441. [Google Scholar] [CrossRef]
- Petro, J.L.; Gallo-Villegas, J.; Calderón, J.C. Myonectin and metabolic health: a systematic review. Front Endocrinol (Lausanne) 2025, 16, 1557142. [Google Scholar] [CrossRef] [PubMed]
- Orioli, L.; Thissen, J.-P. Myokines as potential mediators of changes in glucose homeostasis and muscle mass after bariatric surgery. Frontiers in Endocrinology 2025, 16–2025. [Google Scholar] [CrossRef]
- Jung, H.N.; Kim, S.-O.; Jung, C.H.; Lee, W.J.; Kim, M.J.; Cho, Y.K. Preserved Muscle Strength Despite Muscle Mass Loss After Bariatric Metabolic Surgery: a Systematic Review and Meta-analysis. Obesity Surgery 2023, 33((11)), 3422–3430. [Google Scholar] [CrossRef]
- Muñoz-Cánoves, P.; Scheele, C.; Pedersen, B.K.; Serrano, A.L. Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? The FEBS Journal 2013, 280((17)), 4131–4148. [Google Scholar] [CrossRef] [PubMed]
- Gonzalez-Gil, A.M.; Elizondo-Montemayor, L. The Role of Exercise in the Interplay between Myokines, Hepatokines, Osteokines, Adipokines, and Modulation of Inflammation for Energy Substrate Redistribution and Fat Mass Loss: A Review. Nutrients 2020, 12((6)), 1899. [Google Scholar] [CrossRef] [PubMed]
- Petersen, A.M.W.; Pedersen, B.K. The anti-inflammatory effect of exercise. Journal of Applied Physiology 2005, 98((4)), 1154–1162. [Google Scholar] [CrossRef]
- Lightfoot, A.P.; Cooper, R.G. The role of myokines in muscle health and disease. Curr Opin Rheumatol 2016, 28((6)), 661–6. [Google Scholar] [CrossRef]
- Lin, W.; Song, H.; Shen, J.; Wang, J.; Yang, Y.; Yang, Y.; Cao, J.; Xue, L. e.; Zhao, F.; Xiao, T.; Lin, R. Functional role of skeletal muscle-derived interleukin-6 and its effects on lipid metabolism. Frontiers in Physiology 2023, 14–2023. [Google Scholar] [CrossRef]
- Nehme, A.; Zouein, F.A.; Zayeri, Z.D.; Zibara, K. An Update on the Tissue Renin Angiotensin System and Its Role in Physiology and Pathology. J Cardiovasc Dev Dis 2019, 6((2)). [Google Scholar] [CrossRef] [PubMed]
- Dandona, P.; Dhindsa, S.; Ghanim, H.; Chaudhuri, A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. Journal of Human Hypertension 2007, 21((1)), 20–27. [Google Scholar] [CrossRef] [PubMed]
- Hu, Y.; Zhao, D.; Zhong, L.; Zheng, J.; Zhang, D.; Wu, E.; Shi, Q.; Qiao, L.; Lin, L. Integrated multi-omics analysis reveals metabolic reprogramming as a key driver of angiotensin II-induced vascular remodeling. VIEW 2026, 7((1)), 20250146. [Google Scholar] [CrossRef]
- da Silva, A.A.; do Carmo, J.M.; Li, X.; Wang, Z.; Mouton, A.J.; Hall, J.E. Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited. Can J Cardiol 2020, 36((5)), 671–682. [Google Scholar] [CrossRef] [PubMed]
- Chang, Y.W.; Hung, L.C.; Chen, Y.C.; Wang, W.H.; Lin, C.Y.; Tzeng, H.H.; Suen, J.L.; Chen, Y.H. Insulin Reduces Inflammation by Regulating the Activation of the NLRP3 Inflammasome. Front Immunol 2020, 11, 587229. [Google Scholar] [CrossRef]
- Kim, N.; Jung, Y.; Nam, M.; Sun Kang, M.; Lee, M.K.; Cho, Y.; Choi, E.-K.; Hwang, G.-S.; Soo Kim, H. Angiotensin II affects inflammation mechanisms via AMPK-related signalling pathways in HL-1 atrial myocytes. Scientific Reports 2017, 7((1)), 10328. [Google Scholar] [CrossRef]
- Koumallos, N.; Sigala, E.; Milas, T.; Baikoussis, N.G.; Aragiannis, D.; Sideris, S.; Tsioufis, K. Angiotensin Regulation of Vascular Homeostasis: Exploring the Role of ROS and RAS Blockers. International Journal of Molecular Sciences 2023, 24((15)), 12111. [Google Scholar] [CrossRef]
- Miura, S.-i.; Matsuo, Y.; Seumatsu, Y. Renin-angiotensin-aldosterone system and its relation to hypertension. Hypertension Research 2025, 48((8)), 2209–2217. [Google Scholar] [CrossRef]
- Bo, L.; Wei, L.; Shi, L.; Luo, C.; Gao, S.; Zhou, A.; Mao, C. Altered local RAS in the liver increased the risk of NAFLD in male mouse offspring produced by in vitro fertilization. BMC Pregnancy Childbirth 2023, 23((1)), 345. [Google Scholar] [CrossRef]
- Chaimati, S.; Shantavasinkul, P.C.; Sritara, P.; Sirivarasai, J. Effects of AGT and AGTR1 Genetic Polymorphisms and Changes in Blood Pressure Over a Five-Year Follow-Up. Risk Manag Healthc Policy 2023, 16, 2931–2942. [Google Scholar] [CrossRef]
- Ketkar, H.; Alqahtani, M.; Tang, S.; Parambath, S.P.; Bakshi, C.S.; Jain, S. Chronically hypertensive transgenic mice expressing human AT1R haplotype-I exhibit increased susceptibility to Francisella tularensis. Front Microbiol 2023, 14, 1173577. [Google Scholar] [CrossRef]
- Weber, C.M.; Harris, M.N.; Zic, S.M.; Sangha, G.S.; Arnold, N.S.; Dluzen, D.F.; Clyne, A.M. Angiotensin II Increases Oxidative Stress and Inflammation in Female, But Not Male, Endothelial Cells. Cellular and Molecular Bioengineering 2023, 16((2)), 127–141. [Google Scholar] [CrossRef] [PubMed]
- Mekala, A.; Qiu, H. Interplay Between Vascular Dysfunction and Neurodegenerative Pathology: New Insights into Molecular Mechanisms and Management. Biomolecules 2025, 15((5)), 712. [Google Scholar] [CrossRef]
- Takeda, Y.; Matoba, K.; Sekiguchi, K.; Nagai, Y.; Yokota, T.; Utsunomiya, K.; Nishimura, R. Endothelial Dysfunction in Diabetes. Biomedicines 2020, 8((7)). [Google Scholar] [CrossRef] [PubMed]
- Bazzazzadehgan, S.; Shariat-Madar, Z.; Mahdi, F. Distinct Roles of Common Genetic Variants and Their Contributions to Diabetes: MODY and Uncontrolled T2DM. Biomolecules 2025, 15((3)). [Google Scholar] [CrossRef]
- Tomiyama, H. Vascular function: a key player in hypertension. Hypertension Research 2023, 46((9)), 2145–2158. [Google Scholar] [CrossRef] [PubMed]
- Shariat-Madar, Z.; Mahdi, F. Potential Molecular Biomarkers for Predicting and Monitoring Complications in Type 2 Diabetes Mellitus. Molecules 2025, 30, 22. [Google Scholar] [CrossRef]
- Orieux, A.; Boulestreau, R.; Bats, M.L.; Vaurs, J.; Michot, M.; Peghaire, C.; Duplaa, C.; Couffinhal, T.; Rubin, S. Mechanisms of hypertension: Microvascular lesions and role of inflammation. Archives of Cardiovascular Diseases 2025, 118((6) Supplement 1, S183–S184. [Google Scholar] [CrossRef]
- Yannoutsos, A.; Levy, B.I.; Safar, M.E.; Slama, G.; Blacher, J. Pathophysiology of hypertension: interactions between macro and microvascular alterations through endothelial dysfunction. Journal of Hypertension 2014, 32((2)). [Google Scholar] [CrossRef]
- Committee, t. M. W. The Metabolic Syndrome Is a Risk Indicator of Microvascular and Macrovascular Complications in Diabetes: Results from Metascreen, a multicenter diabetes clinic–based survey. Diabetes Care 2006, 29((12)), 2701–2707. [Google Scholar] [CrossRef] [PubMed]
- Tomiyama, H.; Shiina, K. The Relationships between Micro- and Macrovascular Damages: Their Functional and Morphological Aspects. J Atheroscler Thromb 2022, 29((1)), 1–2. [Google Scholar] [CrossRef]
- Lazdunski, M. Potassium channels: Structure-function relationships, diversity, and pharmacology. Cardiovascular Drugs and Therapy 1992, 6((1)), 313–319. [Google Scholar] [CrossRef]
- Jackson, W.F. Chapter Three - Potassium Channels in Regulation of Vascular Smooth Muscle Contraction and Growth. In Advances in Pharmacology; Khalil, R.A., Ed.; Academic Press, 2017; Vol. 78, pp. 89–144. [Google Scholar]
- Sobey, C.G. Potassium Channel Function in Vascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2001, 21((1)), 28–38. [Google Scholar] [CrossRef]
- Nádasy, G.L.; Balla, A.; Dörnyei, G.; Hunyady, L.; Szekeres, M. Direct Vascular Effects of Angiotensin II (A Systematic Short Review). International Journal of Molecular Sciences 2025, 26((1)), 113. [Google Scholar] [CrossRef]
- Hayabuchi, Y.; Standen, N.B.; Davies, N.W. Angiotensin II inhibits and alters kinetics of voltage-gated K+ channels of rat arterial smooth muscle. American Journal of Physiology-Heart and Circulatory Physiology 2001, 281((6)), H2480–H2489. [Google Scholar] [CrossRef]
- Nieves-Cintrón, M.; Flores-Tamez, V.A.; Le, T.; Baudel, M.M.-A.; Navedo, M.F. Cellular and molecular effects of hyperglycemia on ion channels in vascular smooth muscle. Cellular and Molecular Life Sciences 2021, 78((1)), 31–61. [Google Scholar] [CrossRef]
- Liu, Y.; Gutterman, D.D. The coronary circulation in diabetes:: Influence of reactive oxygen species on K+ channel-mediated vasodilation. Vascular Pharmacology 2002, 38((1)), 43–49. [Google Scholar] [CrossRef]
- Durante, A.; Mazzapicchi, A.; Baiardo Redaelli, M. Systemic and Cardiac Microvascular Dysfunction in Hypertension. International Journal of Molecular Sciences 2024, 25((24)), 13294. [Google Scholar] [CrossRef] [PubMed]
- Alistair, D.G. Hypertensive Cerebral Small Vessel Disease and Stroke. Brain Pathology 2002, 12((3)), 358–370. [Google Scholar] [CrossRef] [PubMed]
- Werner, M.E.; Ledoux, J. K+ channels in biological processes: vascular K+ channels in the regulation of blood pressure. Journal of Receptor, Ligand and Channel Research 2014, 7, 51–60. [Google Scholar] [CrossRef]
- Yang, X.; Yang, Y. The crucial role of potassium ion channels in diabetes mellitus and its complications: A review. Channels 2025, 19((1)), 2531949. [Google Scholar] [CrossRef]
- Jernigan, N.L.; Drummond, H.A. Myogenic vasoconstriction in mouse renal interlobar arteries: role of endogenous β and γENaC. American Journal of Physiology-Renal Physiology 2006, 291((6)), F1184–F1191. [Google Scholar] [CrossRef]
- Oberleithner, H.; Ludwig, T.; Riethmüller, C.; Hillebrand, U.; Albermann, L.; Schäfer, C.; Shahin, V.; Schillers, H. Human Endothelium: Target for Aldosterone. Hypertension 2004, 43((5)), 952–956. [Google Scholar] [CrossRef]
- Mantegazza, M.; Cestèle, S.; Catterall, W.A. Sodium channelopathies of skeletal muscle and brain. Physiological Reviews 2021, 101((4)), 1633–1689. [Google Scholar] [CrossRef]
- Cannon, S.C. Sodium Channelopathies of Skeletal Muscle. In Voltage-gated Sodium Channels: Structure, Function and Channelopathies; Chahine, M., Ed.; Springer International Publishing: Cham, 2018; pp. 309–330. [Google Scholar]
- Pérez, F.R.; Venegas, F.; González, M.; Andrés, S.; Vallejos, C.; Riquelme, G.; Sierralta, J.; Michea, L. Endothelial Epithelial Sodium Channel Inhibition Activates Endothelial Nitric Oxide Synthase via Phosphoinositide 3-Kinase/Akt in Small-Diameter Mesenteric Arteries. Hypertension 2009, 53((6)), 1000–1007. [Google Scholar] [CrossRef]
- Jeggle, P.; Callies, C.; Tarjus, A.; Fassot, C.; Fels, J.; Oberleithner, H.; Jaisser, F.; Kusche-Vihrog, K. Epithelial Sodium Channel Stiffens the Vascular Endothelium In Vitro and in Liddle Mice. Hypertension 2013, 61((5)), 1053–1059. [Google Scholar] [CrossRef] [PubMed]
- Sternak, M.; Bar, A.; Adamski, M.G.; Mohaissen, T.; Marczyk, B.; Kieronska, A.; Stojak, M.; Kus, K.; Tarjus, A.; Jaisser, F.; Chlopicki, S. The Deletion of Endothelial Sodium Channel α (αENaC) Impairs Endothelium-Dependent Vasodilation and Endothelial Barrier Integrity in Endotoxemia in Vivo. Frontiers in Pharmacology 2018, 9, 2018. [Google Scholar] [CrossRef] [PubMed]
- Herzog, M.J.; Müller, P.; Lechner, K.; Stiebler, M.; Arndt, P.; Kunz, M.; Ahrens, D.; Schmeißer, A.; Schreiber, S.; Braun-Dullaeus, R.C. Arterial stiffness and vascular aging: mechanisms, prevention, and therapy. Signal Transduction and Targeted Therapy 2025, 10((1)), 282. [Google Scholar] [CrossRef]
- Vlahu, C.A.; Lemkes, B.A.; Struijk, D.G.; Koopman, M.G.; Krediet, R.T.; Vink, H. Damage of the Endothelial Glycocalyx in Dialysis Patients. Journal of the American Society of Nephrology 2012, 23((11)), 1900–1908. [Google Scholar] [CrossRef]
- Oberleithner, H.; Wilhelmi, M. Vascular Glycocalyx Sodium Store - Determinant of Salt Sensitivity? Blood Purification 2015, 39((1-3)), 7–10. [Google Scholar] [CrossRef]
- Broekhuizen, L.N.; Lemkes, B.A.; Mooij, H.L.; Meuwese, M.C.; Verberne, H.; Holleman, F.; Schlingemann, R.O.; Nieuwdorp, M.; Stroes, E.S.G.; Vink, H. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010, 53((12)), 2646–2655. [Google Scholar] [CrossRef]
- Strojek, K.; Grzeszczak, W.; Lacka, B.; Gorska, J.; Keller, C.K.; Ritz, E. Increased prevalence of salt sensitivity of blood pressure in IDDM with and without microalbuminuria. Diabetologia 1995, 38((12)), 1443–1448. [Google Scholar] [CrossRef]
- Hill, M.A.; Jaisser, F.; Sowers, J.R. Role of the vascular endothelial sodium channel activation in the genesis of pathologically increased cardiovascular stiffness. Cardiovascular Research 2020, 118((1)), 130–140. [Google Scholar] [CrossRef]
- Oberleithner, H.; Peters, W.; Kusche-Vihrog, K.; Korte, S.; Schillers, H.; Kliche, K.; Oberleithner, K. Salt overload damages the glycocalyx sodium barrier of vascular endothelium. Pflügers Archiv - European Journal of Physiology 2011, 462((4)), 519–528. [Google Scholar] [CrossRef] [PubMed]
- Flores, J.; Nugent, K. Sodium, the Vascular Endothelium, and Hypertension: A Narrative Review of Literature. Cardiology in Review 9900. [CrossRef]
- Korte, S.; Wiesinger, A.; Straeter, A.S.; Peters, W.; Oberleithner, H.; Kusche-Vihrog, K. Firewall function of the endothelial glycocalyx in the regulation of sodium homeostasis. Pflügers Archiv - European Journal of Physiology 2012, 463((2)), 269–278. [Google Scholar] [CrossRef] [PubMed]
- McDonald, K.K.; Cooper, S.; Danielzak, L.; Leask, R.L. Glycocalyx Degradation Induces a Proinflammatory Phenotype and Increased Leukocyte Adhesion in Cultured Endothelial Cells under Flow. PLOS ONE 2016, 11((12)), e0167576. [Google Scholar] [CrossRef] [PubMed]
- Zaib, S.; Ahmad, S.; Khan, I.; Bin Jardan, Y.A.; Fentahun Wondmie, G. An evaluation of inflammatory and endothelial dysfunction markers as determinants of peripheral arterial disease in those with diabetes mellitus. Scientific Reports 2024, 14((1)), 15348. [Google Scholar] [CrossRef] [PubMed]
- Lang, P.-P.; Bai, J.; Zhang, Y.-L.; Yang, X.-L.; Xia, Y.-L.; Lin, Q.-Y.; Li, H.-H. Blockade of intercellular adhesion molecule-1 prevents angiotensin II-induced hypertension and vascular dysfunction. Laboratory Investigation 2020, 100((3)), 378–386. [Google Scholar] [CrossRef]
- Guan, X.; Zhu, X.; Zha, L.; Yu, W.; Rao, X.; Xiong, Y.; Jin, Y.; Zhang, M.; Luo, T.; Huang, X.; Wang, X.; Hua, F.; Xu, J. VCAM-1 in Cognitive Impairment: Mechanisms, Biomarker Potential, and Therapeutic Targeting. Aging Dis 2025. [Google Scholar]
- Oberleithner, H.; Riethmüller, C.; Schillers, H.; MacGregor, G.A.; de Wardener, H.E.; Hausberg, M. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proceedings of the National Academy of Sciences 2007, 104((41)), 16281–16286. [Google Scholar] [CrossRef] [PubMed]
- Oberleithner, H. Two barriers for sodium in vascular endothelium? Annals of Medicine 2012, 44((sup1)), S143–S148. [Google Scholar] [CrossRef]
- Monteil, A.; Guérineau, N.C.; Gil-Nagel, A.; Parra-Diaz, P.; Lory, P.; Senatore, A. New insights into the physiology and pathophysiology of the atypical sodium leak channel NALCN. Physiological Reviews 2024, 104((1)), 399–472. [Google Scholar] [CrossRef] [PubMed]
- Cochet-Bissuel, M.; Lory, P.; Monteil, A. The sodium leak channel, NALCN, in health and disease. Front Cell Neurosci 2014, 8, 132. [Google Scholar] [CrossRef] [PubMed]
- Kschonsak, M.; Chua, H.C.; Noland, C.L.; Weidling, C.; Clairfeuille, T.; Bahlke, O.Ø.; Ameen, A.O.; Li, Z.R.; Arthur, C.P.; Ciferri, C.; Pless, S.A.; Payandeh, J. Structure of the human sodium leak channel NALCN. Nature 2020, 587((7833)), 313–318. [Google Scholar] [CrossRef]
- Li, P.; Halabi, C.M.; Stewart, R.; Butler, A.; Brown, B.; Xia, X.; Santi, C.; England, S.; Ferreira, J.; Mecham, R.P.; Salkoff, L. Sodium-activated potassium channels moderate excitability in vascular smooth muscle. The Journal of Physiology 2019, 597((20)), 5093–5108. [Google Scholar] [CrossRef]
- Li, P.; Halabi, C.M.; Stewart, R.; Butler, A.; Brown, B.; Xia, X.; Santi, C.; England, S.; Ferreira, J.; Mecham, R.P.; Salkoff, L. Sodium-activated potassium channels moderate excitability in vascular smooth muscle. J Physiol 2019, 597((20)), 5093–5108. [Google Scholar] [CrossRef]
- Sakitani, N. The sympathetic nervous system in the pathophysiology of hypertension: Mechanistic insights and therapeutic implications. Hypertension Research 2026. [Google Scholar] [CrossRef]
- Wong, C.-O.; Yao, X. TRP Channels in Vascular Endothelial Cells. In Transient Receptor Potential Channels; Islam, M.S., Ed.; Springer Netherlands: Dordrecht, 2011; pp. 759–780. [Google Scholar]
- Zhang, M.; Ma, Y.; Ye, X.; Zhang, N.; Pan, L.; Wang, B. TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases. Signal Transduction and Targeted Therapy 2023, 8((1)), 261. [Google Scholar] [CrossRef]
- Smani, T.; Gómez, L.J.; Regodon, S.; Woodard, G.E.; Siegfried, G.; Khatib, A.M.; Rosado, J.A. TRP Channels in Angiogenesis and Other Endothelial Functions. Front Physiol 2018, 9, 1731. [Google Scholar] [CrossRef]
- Greenberg, H.Z.E.; Carlton-Carew, S.R.E.; Khan, D.M.; Zargaran, A.K.; Jahan, K.S.; Vanessa Ho, W.S.; Albert, A.P. Heteromeric TRPV4/TRPC1 channels mediate calcium-sensing receptor-induced nitric oxide production and vasorelaxation in rabbit mesenteric arteries. Vascul Pharmacol 2017, 96-98, 53–62. [Google Scholar] [CrossRef] [PubMed]
- Feng, S. TRPC Channel Structure and Properties. Adv Exp Med Biol 2017, 976, 9–23. [Google Scholar]
- Kim, J.; Ko, J.; Myeong, J.; Kwak, M.; Hong, C.; So, I. TRPC1 as a negative regulator for TRPC4 and TRPC5 channels. Pflügers Archiv - European Journal of Physiology 2019, 471((8)), 1045–1053. [Google Scholar] [CrossRef] [PubMed]
- Xu, S.-Z.; Beech, D.J. TrpC1 Is a Membrane-Spanning Subunit of Store-Operated Ca2+ Channels in Native Vascular Smooth Muscle Cells. Circulation Research 2001, 88((1)), 84–87. [Google Scholar] [CrossRef] [PubMed]
- Krout, D.; Schaar, A.; Sun, Y.; Sukumaran, P.; Roemmich, J.N.; Singh, B.B.; Claycombe-Larson, K.J. The TRPC1 Ca2+-permeable channel inhibits exercise-induced protection against high-fat diet-induced obesity and type II diabetes. Journal of Biological Chemistry 2017, 292((50)), 20799–20807. [Google Scholar] [CrossRef]
- Chen, X.; Sooch, G.; Demaree, I.S.; White, F.A.; Obukhov, A.G. Transient Receptor Potential Canonical (TRPC) Channels: Then and Now. Cells 2020, 9((9)). [Google Scholar] [CrossRef]
- Kuang, C.Y.; Yu, Y.; Wang, K.; Qian, D.H.; Den, M.Y.; Huang, L. Knockdown of transient receptor potential canonical-1 reduces the proliferation and migration of endothelial progenitor cells. Stem Cells Dev 2012, 21((3)), 487–96. [Google Scholar] [CrossRef]
- Bishara, N.B.; Ding, H. Glucose enhances expression of TRPC1 and calcium entry in endothelial cells. Am J Physiol Heart Circ Physiol 2010, 298((1)), H171–H178. [Google Scholar] [CrossRef]
- van Breemen, C.; Poburko, D.; Okon, E.B. TRP proteins: a new dimension in the treatment of occlusive vascular disease. Circ Res 2006, 98((4)), 446–447. [Google Scholar] [CrossRef]
- Tang, L.; Yao, F.; Wang, H.; Wang, X.; Shen, J.; Dai, B.; Wu, H.; Zhou, D.; Guo, F.; Wang, J.; Li, T.; Wang, H.; Gong, T.; Su, J.; Wang, L.; Liang, P. Inhibition of TRPC1 prevents cardiac hypertrophy via NF-κB signaling pathway in human pluripotent stem cell-derived cardiomyocytes. Journal of Molecular and Cellular Cardiology 2019, 126, 143–154. [Google Scholar] [CrossRef] [PubMed]
- Chen, K.; Jin, X.; Li, Q.; Wang, W.; Wang, Y.; Zhang, J. Association of TRPC1 Gene Polymorphisms with Type 2 Diabetes and Diabetic Nephropathy in Han Chinese Population. Endocrine Research 2013, 38((2)), 59–68. [Google Scholar] [CrossRef]
- Zhu, Y.; Chu, Y.; Lan, Y.; Wang, S.; Zhang, Y.; Liu, Y.; Wang, X.; Yu, F.; Ma, X. Loss of Endothelial TRPC1 Induces Aortic Hypercontractility and Hypertension. Circulation Research 2025, 136((5)), 508–523. [Google Scholar] [CrossRef]
- Takahashi, Y.; Watanabe, H.; Murakami, M.; Ohba, T.; Radovanovic, M.; Ono, K.; Iijima, T.; Ito, H. Involvement of transient receptor potential canonical 1 (TRPC1) in angiotensin II-induced vascular smooth muscle cell hypertrophy. Atherosclerosis 2007, 195((2)), 287–296. [Google Scholar] [CrossRef] [PubMed]
- Wen, X.; Peng, Y.; Yang, W.; Zhu, Y.; Yu, F.; Geng, L.; Wang, X.; Wang, X.; Zhang, X.; Tang, Y.; Feng, L.; Zhou, T.; Jia, H.; Yang, L. VSMC-specific TRPC1 deletion attenuates angiotensin II-induced hypertension and cardiovascular remodeling. Journal of Molecular Medicine 2025, 103((2)), 205–218. [Google Scholar] [CrossRef] [PubMed]
- Paria, B.C.; Malik, A.B.; Kwiatek, A.M.; Rahman, A.; May, M.J.; Ghosh, S.; Tiruppathi, C. Tumor necrosis factor-alpha induces nuclear factor-kappaB-dependent TRPC1 expression in endothelial cells. J Biol Chem 2003, 278((39)), 37195–37203. [Google Scholar] [CrossRef]
- Alvarez, D.F.; King, J.A.; Weber, D.; Addison, E.; Liedtke, W.; Townsley, M.I. Transient receptor potential vanilloid 4-mediated disruption of the alveolar septal barrier: a novel mechanism of acute lung injury. Circ Res 2006, 99((9)), 988–995. [Google Scholar] [CrossRef]
- Loot, A.E.; Popp, R.; Fisslthaler, B.; Vriens, J.; Nilius, B.; Fleming, I. Role of cytochrome P450-dependent transient receptor potential V4 activation in flow-induced vasodilatation. Cardiovasc Res 2008, 80((3)), 445–452. [Google Scholar] [CrossRef]
- Freichel, M.; Suh, S.H.; Pfeifer, A.; Schweig, U.; Trost, C.; Weissgerber, P.; Biel, M.; Philipp, S.; Freise, D.; Droogmans, G.; Hofmann, F.; Flockerzi, V.; Nilius, B. Lack of an endothelial store-operated Ca2+ current impairs agonist-dependent vasorelaxation in TRP4-/- mice. Nat Cell Biol 2001, 3((2)), 121–127. [Google Scholar] [CrossRef]
- Yeon, S.-I.; Kim, J.Y.; Yeon, D.-S.; Abramowitz, J.; Birnbaumer, L.; Muallem, S.; Lee, Y.-H. Transient Receptor Potential Canonical Type 3 Channels Control the Vascular Contractility of Mouse Mesenteric Arteries. PLOS ONE 2014, 9((10)), e110413. [Google Scholar] [CrossRef]
- Du, J.; Ma, X.; Shen, B.; Huang, Y.; Birnbaumer, L.; Yao, X. TRPV4, TRPC1, and TRPP2 assemble to form a flow-sensitive heteromeric channel. The FASEB Journal 2014, 28((11)), 4677–4685. [Google Scholar] [CrossRef] [PubMed]
- Earley, S. TRPA1 channels in the vasculature. Br J Pharmacol 2012, 167((1)), 13–22. [Google Scholar] [CrossRef]
- Palmer, A.K.; Jensen, M.D. Metabolic changes in aging humans: current evidence and therapeutic strategies. J Clin Invest 2022, 132, 16. [Google Scholar] [CrossRef]
- McCarthy, K.; Laird, E.; O’Halloran, A.M.; Fallon, P.; O’Connor, D.; Ortuño, R.R.; Kenny, R.A. An examination of the prevalence of metabolic syndrome in older adults in Ireland: Findings from The Irish Longitudinal Study on Ageing (TILDA). PLOS ONE 2022, 17((9)), e0273948. [Google Scholar] [CrossRef]
- McCarthy, K.; O'Halloran, A.M.; Fallon, P.; Kenny, R.A.; McCrory, C. Metabolic syndrome accelerates epigenetic ageing in older adults: Findings from The Irish Longitudinal Study on Ageing (TILDA). Experimental Gerontology 2023, 183, 112314. [Google Scholar] [CrossRef]
- Caso, G.; McNurlan, M.A.; Mileva, I.; Zemlyak, A.; Mynarcik, D.C.; Gelato, M.C. Peripheral fat loss and decline in adipogenesis in older humans. Metabolism 2013, 62((3)), 337–340. [Google Scholar] [CrossRef] [PubMed]
- Kornicka, K.; Marycz, K.; Tomaszewski, K.A.; Marędziak, M.; Śmieszek, A. The Effect of Age on Osteogenic and Adipogenic Differentiation Potential of Human Adipose Derived Stromal Stem Cells (hASCs) and the Impact of Stress Factors in the Course of the Differentiation Process. Oxid Med Cell Longev 2015, 2015, 309169. [Google Scholar] [CrossRef]
- López-Otín, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. Hallmarks of aging: An expanding universe. Cell 2023, 186((2)), 243–278. [Google Scholar] [CrossRef]
- Guo, J.; Huang, X.; Dou, L.; Yan, M.; Shen, T.; Tang, W.; Li, J. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduction and Targeted Therapy 2022, 7((1)), 391. [Google Scholar] [CrossRef] [PubMed]
- Tartiere, A.G.; Freije, J.M.P.; López-Otín, C. The hallmarks of aging as a conceptual framework for health and longevity research. Frontiers in Aging 2024, 5–2024. [Google Scholar] [CrossRef]
- Lindahl, T. Instability and decay of the primary structure of DNA. Nature 1993, 362((6422)), 709–715. [Google Scholar] [CrossRef]
- Kallai, A.; Ungvari, Z.; Fekete, M.; Maier, A.B.; Mikala, G.; Andrikovics, H.; Lehoczki, A. Genomic instability and genetic heterogeneity in aging: insights from clonal hematopoiesis (CHIP), monoclonal gammopathy (MGUS), and monoclonal B-cell lymphocytosis (MBL). Geroscience 2025, 47((1)), 703–720. [Google Scholar] [CrossRef]
- Meramat, A.; Rajab, N.; Shahar, S.; Sharif, R. Cognitive impairment, genomic instability and trace elements. The Journal of nutrition, health and aging 2015, 19((1)), 48–57. [Google Scholar] [CrossRef] [PubMed]
- Choi, H.-J.; Han, H.-S.; Park, J.-H.; Son, J.-H.; Bae, J.-H.; Seung, T.-S.; Choi, C. Antioxidantive, Phospholipase $ A_2 $ Inhibiting, and Anticancer Effect of Polyphenol Rich Fractions from Panax ginseng CA Meyer. Applied Biological Chemistry 2003, 46((3)), 251–256. [Google Scholar]
- Liu, S.; Zhao, J.; Liu, Y.; Li, N.; Wang, Z.; Wang, X.; Liu, X.; Jiang, L.; Liu, B.; Fu, X. High chromosomal stability and immortalized totipotency characterize long-term tissue cultures of Chinese Ginseng (Panax ginseng). Genes 2021, 12((4)), 514. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.Y.; Park, J.Y.; Kang, H.J.; Kim, O.Y.; Lee, J.H. Beneficial effects of Korean red ginseng on lymphocyte DNA damage, antioxidant enzyme activity, and LDL oxidation in healthy participants: a randomized, double-blind, placebo-controlled trial. Nutrition journal 2012, 11((1)), 47. [Google Scholar] [CrossRef]
- Szeto, Y.T.; Sin, Y.S.P.; Pak, S.C.; Kalle, W. American ginseng tea protects cellular DNA within 2 h from consumption: results of a pilot study in healthy human volunteers. International journal of food sciences and nutrition 2015, 66((7)), 815–818. [Google Scholar] [CrossRef]
- Szeto, Y.T.; Lee, L.K. Rapid but mild genoprotective effect on lymphocytic DNA with Panax notoginseng extract supplementation. J Intercult Ethnopharmacol 2014, 3((4)), 155–158. [Google Scholar] [CrossRef]
- Razavi-Azarkhiavi, K.; Behravan, J.; Mosaffa, F.; Sehatbakhsh, S.; Shirani, K.; Karimi, G. Protective effects of aqueous and ethanol extracts of rosemary on H2O2-induced oxidative DNA damage in human lymphocytes by comet assay. J Complement Integr Med 2014, 11((1)), 27–33. [Google Scholar] [CrossRef]
- Bakuradze, T.; Meiser, P.; Galan, J.; Richling, E. DNA Protection by an Aronia Juice-Based Food Supplement. Antioxidants (Basel) 2021, 10((6)). [Google Scholar] [CrossRef] [PubMed]
- Del Bó, C.; Riso, P.; Campolo, J.; Møller, P.; Loft, S.; Klimis-Zacas, D.; Brambilla, A.; Rizzolo, A.; Porrini, M. A single portion of blueberry (Vaccinium corymbosum L) improves protection against DNA damage but not vascular function in healthy male volunteers. Nutr Res 2013, 33((3)), 220–227. [Google Scholar] [CrossRef] [PubMed]
- Blackburn, E.H. The molecular structure of centromeres and telomeres. Annu Rev Biochem 1984, 53, 163–194. [Google Scholar] [CrossRef]
- Blackburn, E.H. Telomere states and cell fates. Nature 2000, 408((6808)), 53–56. [Google Scholar] [CrossRef]
- Casagrande, S.; Hau, M. Telomere attrition: metabolic regulation and signalling function? Biology Letters 2019, 15((3)). [Google Scholar] [CrossRef]
- von Zglinicki, T. Oxidative stress shortens telomeres. Trends Biochem Sci 2002, 27((7)), 339–344. [Google Scholar] [CrossRef]
- Haycock, P.C.; Heydon, E.E.; Kaptoge, S.; Butterworth, A.S.; Thompson, A.; Willeit, P. Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. Bmj 2014, 349. [Google Scholar] [CrossRef]
- Weischer, M.; Bojesen, S.E.; Cawthon, R.M.; Freiberg, J.J.; Tybjærg-Hansen, A.; Nordestgaard, B.G. Short telomere length, myocardial infarction, ischemic heart disease, and early death. Arteriosclerosis, thrombosis, and vascular biology 2012, 32((3)), 822–829. [Google Scholar] [CrossRef]
- Willeit, P.; Raschenberger, J.; Heydon, E.E.; Tsimikas, S.; Haun, M.; Mayr, A.; Weger, S.; Witztum, J.L.; Butterworth, A.S.; Willeit, J.; Kronenberg, F.; Kiechl, S. Leucocyte Telomere Length and Risk of Type 2 Diabetes Mellitus: New Prospective Cohort Study and Literature-Based Meta-Analysis. PLOS ONE 2014, 9((11)), e112483. [Google Scholar] [CrossRef] [PubMed]
- Sun, C.; Qiu, P.; Huang, S.; Luo, Q.; Ma, Q.; Hu, P.; Chen, F.; Wu, H.; Chen, C. Telomere length and metabolic dysfunction-associated steatotic liver disease risk and progression: A systematic review and meta-analysis. Experimental Gerontology 2026, 214, 113036. [Google Scholar] [CrossRef]
- Barros, A.G.A.; Soares, T.O.; Lage, A.F.A.; Cintra, M.T.G.; de Paula, J.J.; Malheiro, O.B.; Falcão, A.E.; Nogueira, C.A.C.; de Carvalho, L.B.; Romano Silva, M.A.; de Miranda, D.M.; Viana, B.M.; Rosa, D.V.F.; Bicalho, M.A.C. Leukocyte telomere attrition in cognitive decline: associations with APOE genotype and cardiovascular risk factors. Front Aging Neurosci 2025, 17, 1557016. [Google Scholar] [CrossRef]
- Cohen-Manheim, I.; Doniger, G.M.; Sinnreich, R.; Simon, E.S.; Pinchas, R.; Aviv, A.; Kark, J.D. Increased attrition of leukocyte telomere length in young adults is associated with poorer cognitive function in midlife. Eur J Epidemiol 2016, 31((2)), 147–157. [Google Scholar] [CrossRef]
- Koh, S.H.; Choi, S.H.; Jeong, J.H.; Jang, J.W.; Park, K.W.; Kim, E.J.; Kim, H.J.; Hong, J.Y.; Yoon, S.J.; Yoon, B.; Kang, J.H.; Lee, J.M.; Park, H.H.; Ha, J.; Suh, Y.J.; Kang, S. Telomere shortening reflecting physical aging is associated with cognitive decline and dementia conversion in mild cognitive impairment due to Alzheimer's disease. Aging (Albany NY) 2020, 12((5)), 4407–4423. [Google Scholar] [CrossRef]
- Martin-Ruiz, C.; Dickinson, H.O.; Keys, B.; Rowan, E.; Kenny, R.A.; Von Zglinicki, T. Telomere length predicts poststroke mortality, dementia, and cognitive decline. Ann Neurol 2006, 60((2)), 174–180. [Google Scholar] [CrossRef]
- Cai, Z.; Yan, L.J.; Ratka, A. Telomere shortening and Alzheimer's disease. Neuromolecular Med 2013, 15((1)), 25–48. [Google Scholar] [CrossRef]
- Pudas, S.; Josefsson, M.; Nordin Adolfsson, A.; Landfors, M.; Kauppi, K.; Veng-Taasti, L.M.; Hultdin, M.; Adolfsson, R.; Degerman, S. Short Leukocyte Telomeres, But Not Telomere Attrition Rates, Predict Memory Decline in the 20-Year Longitudinal Betula Study. J Gerontol A Biol Sci Med Sci 2021, 76((6)), 955–963. [Google Scholar] [CrossRef]
- Beyne-Rauzy, O.; Prade-Houdellier, N.; Demur, C.; Recher, C.; Ayel, J.; Laurent, G.; Mansat-De Mas, V. Tumor necrosis factor-α inhibits hTERT gene expression in human myeloid normal and leukemic cells. Blood 2005, 106((9)), 3200–3205. [Google Scholar] [CrossRef] [PubMed]
- Blackburn, E.H. Switching and signaling at the telomere. Cell 2001, 106((6)), 661–673. [Google Scholar] [CrossRef]
- Martínez-Iglesias, O.; Naidoo, V.; Carrera, I.; Corzo, L.; Cacabelos, R. Natural bioactive products as epigenetic modulators for treating neurodegenerative disorders. Pharmaceuticals 2023, 16((2)), 216. [Google Scholar] [CrossRef] [PubMed]
- Ahmed, M. Targeting aging pathways with natural compounds: a review of curcumin, epigallocatechin gallate, thymoquinone, and resveratrol. Immunity & Ageing: I & A 2025, 22, 28. [Google Scholar]
- Moghadam, D.; Zarei, R.; Vakili, S.; Ghojoghi, R.; Zarezade, V.; Veisi, A.; Sabaghan, M.; Azadbakht, O.; Behrouj, H. The effect of natural polyphenols Resveratrol, Gallic acid, and Kuromanin chloride on human telomerase reverse transcriptase (hTERT) expression in HepG2 hepatocellular carcinoma: role of SIRT1/Nrf2 signaling pathway and oxidative stress. Mol Biol Rep 2023, 50((1)), 77–84. [Google Scholar] [CrossRef] [PubMed]
- Uddin, M.J.; Farjana, M.; Moni, A.; Hossain, K.S.; Hannan, M.A.; Ha, H. Prospective Pharmacological Potential of Resveratrol in Delaying Kidney Aging. Int J Mol Sci 2021, 22((15)). [Google Scholar] [CrossRef]
- Farhat, G.; Malla, J.; Hanson, L.; Vadher, J.; Al-Dujaili, E.A.S. Effects of Pomegranate Extract on IGF-1 Levels and Telomere Length in Older Adults (55-70 Years): Findings from a Randomised Double-Blinded Controlled Trial. Nutrients 2025, 17, 18. [Google Scholar] [CrossRef] [PubMed]
- Higashi, Y.; Sukhanov, S.; Anwar, A.; Shai, S.-Y.; Delafontaine, P. IGF-1, oxidative stress and atheroprotection. Trends in Endocrinology & Metabolism 2010, 21((4)), 245–254. [Google Scholar] [CrossRef]
- Serri, O.; Li, L.; Maingrette, F.; Jaffry, N.; Renier, G. v. Enhanced lipoprotein lipase secretion and foam cell formation by macrophages of patients with growth hormone deficiency: possible contribution to increased risk of atherogenesis? The Journal of Clinical Endocrinology & Metabolism 2004, 89((2)), 979–985. [Google Scholar] [CrossRef] [PubMed]
- Sukhanov, S.; Higashi, Y.; Shai, S.-Y.; Vaughn, C.; Mohler, J.; Li, Y.; Song, Y.-H.; Titterington, J.; Delafontaine, P. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arteriosclerosis, thrombosis, and vascular biology 2007, 27((12)), 2684–2690. [Google Scholar] [CrossRef] [PubMed]
- de Jaeger, C.; Kruiskamp, S.; Voronska, E.; Lamberti, C.; Baramki, H.; Beaudeux, J.L.; Cherin, P. A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrients 2024, 16, 17. [Google Scholar] [CrossRef]
- de Jesus, B.B.; Schneeberger, K.; Vera, E.; Tejera, A.; Harley, C.B.; Blasco, M.A. The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging cell 2011, 10((4)), 604–621. [Google Scholar] [CrossRef]
- Harley, C.B.; Liu, W.; Flom, P.L.; Raffaele, J.M. A natural product telomerase activator as part of a health maintenance program: metabolic and cardiovascular response. Rejuvenation research 2013, 16((5)), 386–395. [Google Scholar] [CrossRef]
- Le Saux, C.J.; Davy, P.; Brampton, C.; Ahuja, S.S.; Fauce, S.; Shivshankar, P.; Nguyen, H.; Ramaseshan, M.; Tressler, R.; Pirot, Z. A novel telomerase activator suppresses lung damage in a murine model of idiopathic pulmonary fibrosis. PloS one 2013, 8((3)), e58423. [Google Scholar] [CrossRef]
- Asakawa, Y.; Matsuda, R.; Takemoto, T. Mono-and sesquiterpenoids from Hydrocotyle and Centella species. Phytochemistry 1982, 21((10)), 2590–2592. [Google Scholar] [CrossRef]
- Bandara, M.S.; Lee, E.L.; Thomas, J.E. Gotu Kola (Centella asiatica L.): An under-utilized herb. The Americas Journal of Plant Science and Biotechnology 2011, 5((2)), 20–31. [Google Scholar]
- Leung, A.Y. Traditional Toxicity Documentation of Chinese Materia Medica—An Overview. Toxicologic Pathology 2006, 34((4)), 319–326. [Google Scholar] [CrossRef]
- Tsoukalas, D.; Fragkiadaki, P.; Docea, A.O.; Alegakis, A.K.; Sarandi, E.; Thanasoula, M.; Spandidos, D.A.; Tsatsakis, A.; Razgonova, M.P.; Calina, D. Discovery of potent telomerase activators: Unfolding new therapeutic and anti-aging perspectives. Mol Med Rep 2019, 20((4)), 3701–3708. [Google Scholar] [CrossRef]
- Praengam, K.; Tuntipopipat, S.; Muangnoi, C.; Jangwangkorn, C.; Piamkulvanich, O. Efficacy of a dietary supplement derived from five edible plants on telomere length in Thai adults: A randomized, double-blind, placebo-controlled trial. Food Sci Nutr 2024, 12((3)), 1592–1604. [Google Scholar] [CrossRef]
- Wiriyachitra, P.; Leelahagul, P.; Watanapokasin, R. Regenerative Innovation from Fortified Mangosteen Extract. Clin Immunol Res 2025, 9((1)), 1–6. [Google Scholar] [CrossRef]
- Gontar, Ł.; Geszprych, A.; Drutowska, A.; Osińska, E. Essential oil and phenolic compounds in different organs and developmental stages of Monarda didyma L., and their biological activity. Planta 2025, 261((2)), 37. [Google Scholar] [CrossRef] [PubMed]
- Yao, Q.; Lin, M.T.; Zhu, Y.D.; Xu, H.L.; Zhao, Y.Z. Recent Trends in Potential Therapeutic Applications of the Dietary Flavonoid Didymin. Molecules 2018, 23((10)). [Google Scholar] [CrossRef] [PubMed]
- Campisi, M.; Cannella, L.; Paccagnella, O.; Brazzale, A.R.; Agnolin, A.; Grothe, T.; Baumann, J.; Pavanello, S. Unveiling the geroprotective potential of Monarda didyma L.: insights from in vitro studies and a randomized clinical trial on slowing biological aging and improving quality of life. Geroscience 2025, 47((3)), 4253–4290. [Google Scholar] [CrossRef]
- Forouzanfar, F.; Majeed, M.; Jamialahmadi, T.; Sahebkar, A. Telomerase: A Target for Therapeutic Effects of Curcumin in Cancer. Adv Exp Med Biol 2021, 1286, 135–143. [Google Scholar]
- Khaw, A.K.; Hande, M.P.; Kalthur, G.; Hande, M.P. Curcumin inhibits telomerase and induces telomere shortening and apoptosis in brain tumour cells. J Cell Biochem 2013, 114((6)), 1257–1270. [Google Scholar] [CrossRef]
- Rowaiye, A.B.; Mendes, Y.J.T.; Olofinsae, S.A.; Oche, J.B.; Oladipo, O.H.; Okpalefe, O.A.; Ogidigo, J.O. Camptothecin shows better promise than Curcumin in the inhibition of the Human Telomerase: A computational study. Heliyon 2021, 7((8)), e07742. [Google Scholar] [CrossRef]
- Capasso, L.; De Masi, L.; Sirignano, C.; Maresca, V.; Basile, A.; Nebbioso, A.; Rigano, D.; Bontempo, P. Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential. Molecules 2025, 30((3)). [Google Scholar] [CrossRef]
- Udroiu, I.; Marinaccio, J.; Sgura, A. Epigallocatechin-3-gallate induces telomere shortening and clastogenic damage in glioblastoma cells. Environ Mol Mutagen 2019, 60((8)), 683–692. [Google Scholar] [CrossRef]
- Berger, S.L.; Kouzarides, T.; Shiekhattar, R.; Shilatifard, A. An operational definition of epigenetics. Genes Dev 2009, 23((7)), 781–783. [Google Scholar] [CrossRef]
- Gonzalo, S. Epigenetic alterations in aging. Journal of Applied Physiology 2010, 109((2)), 586–597. [Google Scholar] [CrossRef]
- López-Otín, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. The Hallmarks of Aging. Cell 2013, 153((6)), 1194–1217. [Google Scholar] [CrossRef] [PubMed]
- Abbas, M.N.; Kausar, S.; Cui, H. Therapeutic potential of natural products in glioblastoma treatment: targeting key glioblastoma signaling pathways and epigenetic alterations. Clinical and Translational Oncology 2020, 22((7)), 963–977. [Google Scholar] [CrossRef] [PubMed]
- Dorna, D.; Grabowska, A.; Paluszczak, J. Natural products modulating epigenetic mechanisms by affecting histone methylation/demethylation: Targeting cancer cells. British Journal of Pharmacology 2025, 182((10)), 2137–2158. [Google Scholar] [CrossRef]
- Sawesi, S.; Malkaram, S.A.; Abd Elmageed, Z.Y.; Fandy, T.E. Modulation of the activity of histone lysine methyltransferases and demethylases by curcumin analog in leukaemia cells. Journal of Cellular and Molecular Medicine 2022, 26((22)), 5624–5633. [Google Scholar] [CrossRef]
- Evans, L.W.; Stratton, M.S.; Ferguson, B.S. Dietary natural products as epigenetic modifiers in aging-associated inflammation and disease. Natural Product Reports 2020, 37((5)), 653–676. [Google Scholar] [CrossRef]
- Lai, Z.; Ke, L.; Zhao, W. Naringenin as a neurotherapeutic agent in Alzheimer’s disease: epigenetic signatures, gut microbiota alterations, and molecular neuroprotection. Frontiers in Aging Neuroscience 2025, 17, 1647967. [Google Scholar] [CrossRef]
- Liu, H.-l.; Chen, Y.; Cui, G.-h.; Zhou, J.-f. Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation. Acta Pharmacologica Sinica 2005, 26((5)), 603–609. [Google Scholar] [CrossRef] [PubMed]
- Chang, X.; Rong, C.; Chen, Y.; Yang, C.; Hu, Q.; Mo, Y.; Zhang, C.; Gu, X.; Zhang, L.; He, W. (−)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer׳ s disease model mice by upregulating neprilysin expression. Experimental cell research 2015, 334((1)), 136–145. [Google Scholar] [CrossRef] [PubMed]
- Evans, L.W.; Stratton, M.S.; Ferguson, B.S. Dietary natural products as epigenetic modifiers in aging-associated inflammation and disease. Nat Prod Rep 2020, 37((5)), 653–676. [Google Scholar] [CrossRef]
- Donmez, G.; Arun, A.; Chung, C.-Y.; McLean, P.J.; Lindquist, S.; Guarente, L. SIRT1 protects against α-synuclein aggregation by activating molecular chaperones. Journal of Neuroscience 2012, 32((1)), 124–132. [Google Scholar] [CrossRef] [PubMed]
- Hardy, T.M.; Tollefsbol, T.O. Epigenetic diet: impact on the epigenome and cancer. Epigenomics 2011, 3((4)), 503–518. [Google Scholar] [CrossRef]
- Sanada, F.; Hayashi, S.; Morishita, R. Targeting the hallmarks of aging: mechanisms and therapeutic opportunities. Front Cardiovasc Med 2025, 12, 1631578. [Google Scholar] [CrossRef]
- Shukla, M.; Narayan, M. Proteostasis and Its Role in Disease Development. Cell Biochemistry and Biophysics 2025, 83((2)), 1725–1741. [Google Scholar] [CrossRef]
- Labbadia, J.; Morimoto, R.I. The biology of proteostasis in aging and disease. Annu Rev Biochem 2015, 84, 435–64. [Google Scholar] [CrossRef]
- Almeida, M.F.; Strangman, W.; Bahr, B.A. Distinct ginseng extracts produce disparate effects on proteostatic support through the autophagy-lysosomal pathway that is linked to synaptic resilience and cognitive health. The FASEB Journal 2022, 36, S1. [Google Scholar] [CrossRef]
- Hofer, S.J.; Simon, A.K.; Bergmann, M.; Eisenberg, T.; Kroemer, G.; Madeo, F. Mechanisms of spermidine-induced autophagy and geroprotection. Nat Aging 2022, 2((12)), 1112–1129. [Google Scholar] [CrossRef] [PubMed]
- Scrivo, A.; Bourdenx, M.; Pampliega, O.; Cuervo, A.M. Selective autophagy as a potential therapeutic target for neurodegenerative disorders. Lancet Neurol 2018, 17((9)), 802–815. [Google Scholar] [CrossRef]
- Ma, Y.; Qi, L.; Zhu, F.; Xiao, M.; Li, M.; Zhang, X.; Yuan, X.; Wang, Y.; Sun, C.; Wu, H. Association between dietary spermidine intake and cognitive performance in older adults: The U.S. National Health and Nutrition Examination Survey, 2011–2014. Journal of Affective Disorders 2025(381), 174–182. [CrossRef]
- Yan, L.; Deng, Y.; Gao, J.; Liu, Y.; Li, F.; Shi, J.; Gong, Q. Icariside II Effectively Reduces Spatial Learning and Memory Impairments in Alzheimer’s Disease Model Mice Targeting Beta-Amyloid Production. Frontiers in Pharmacology 2017, 8–2017. [Google Scholar] [CrossRef]
- Joshi, V.; Mishra, R.; Upadhyay, A.; Amanullah, A.; Poluri, K.M.; Singh, S.; Kumar, A.; Mishra, A. Polyphenolic flavonoid (Myricetin) upregulated proteasomal degradation mechanisms: Eliminates neurodegenerative proteins aggregation. Journal of Cellular Physiology 2019, 234((11)), 20900–20914. [Google Scholar] [CrossRef]
- Green, D.R.; Galluzzi, L.; Kroemer, G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 2011, 333((6046)), 1109–1112. [Google Scholar] [CrossRef] [PubMed]
- Lowell, B.B.; Shulman, G.I. Mitochondrial Dysfunction and Type 2 Diabetes. Science 2005, 307((5708)), 384–387. [Google Scholar] [CrossRef]
- Pliouta, L.; Lampsas, S.; Kountouri, A.; Korakas, E.; Thymis, J.; Kassi, E.; Oikonomou, E.; Ikonomidis, I.; Lambadiari, V. Mitochondrial Dysfunction in the development and Progression of Cardiometabolic Diseases: A Narrative review. Journal of Clinical Medicine 2025, 14((11)), 3706. [Google Scholar] [CrossRef]
- Liu, F.; Wu, X.; Wang, Z.; Li, A.; Luo, Y.; Cao, J. Mitochondrial dysfunction in postoperative cognitive dysfunction: From preclinical mechanisms to multimodal diagnostics and precision intervention. Ageing Research Reviews 2025, 111, 102845. [Google Scholar] [CrossRef] [PubMed]
- Zheng, M.; Bai, Y.; Sun, X.; Fu, R.; Liu, L.; Liu, M.; Li, Z.; Huang, X. Resveratrol Reestablishes Mitochondrial Quality Control in Myocardial Ischemia/Reperfusion Injury through Sirt1/Sirt3-Mfn2-Parkin-PGC-1α Pathway. Molecules 2022, 27, 17. [Google Scholar] [CrossRef]
- Yu, H.; Chen, B.; Ren, Q. Baicalin relieves hypoxia-aroused H9c2 cell apoptosis by activating Nrf2/HO-1-mediated HIF1α/BNIP3 pathway. Artif Cells Nanomed Biotechnol 2019, 47((1)), 3657–3663. [Google Scholar] [CrossRef]
- Motoo, Y.; Sawabu, N. Antitumor effects of saikosaponins, baicalin and baicalein on human hepatoma cell lines. Cancer Lett 1994, 86((1)), 91–95. [Google Scholar] [CrossRef]
- Zhu, J.; Wang, J.; Sheng, Y.; Zou, Y.; Bo, L.; Wang, F.; Lou, J.; Fan, X.; Bao, R.; Wu, Y.; Chen, F.; Deng, X.; Li, J. Baicalin improves survival in a murine model of polymicrobial sepsis via suppressing inflammatory response and lymphocyte apoptosis. PLoS One 2012, 7((5)), e35523. [Google Scholar] [CrossRef]
- Chen, M.; Peng, L.; Gong, P.; Zheng, X.; Sun, T.; Zhang, X.; Huo, J. Baicalein induces mitochondrial autophagy to prevent Parkinson's disease in rats via miR-30b and the SIRT1/AMPK/mTOR pathway. Frontiers in Neurology 2022, 12, 646817. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.; Zhang, X.; Yang, Y.; Wang, H.; Yang, X.; Xuan, L.; Yang, D.; Zhang, G.; Wang, Y. Baicalein protects against heart failure by improving mitochondrial dysfunction and regulating endoplasmic reticulum stress to reduce apoptosis in vitro and in vivo. International Journal of Immunopathology and Pharmacology 2025, 39, 03946320251315800. [Google Scholar] [CrossRef]
- Chen, Y.; Zhang, J.; Zhang, M.; Song, Y.; Zhang, Y.; Fan, S.; Ren, S.; Fu, L.; Zhang, N.; Hui, H.; Shen, X. Baicalein resensitizes tamoxifen-resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia-inducible factor-1α. Clinical and Translational Medicine 2021, 11((11)), e577. [Google Scholar] [CrossRef]
- Pottoo, F.H.; Ibrahim, A.M.; Alammar, A.; Alsinan, R.; Aleid, M.; Alshehhi, A.; Alshehri, M.; Mishra, S.; Alhajri, N. Thymoquinone: Review of Its Potential in the Treatment of Neurological Diseases. Pharmaceuticals 2022, 15((4)), 408. [Google Scholar] [CrossRef]
- Khalifa, A.A.; Rashad, R.M.; El-Hadidy, W.F. Thymoquinone protects against cardiac mitochondrial DNA loss, oxidative stress, inflammation and apoptosis in isoproterenol-induced myocardial infarction in rats. Heliyon 2021, 7((7)). [Google Scholar] [CrossRef] [PubMed]
- Zhao, D.; Liu, K.; Wang, J.; Shao, H. Syringin exerts anti-inflammatory and antioxidant effects by regulating SIRT1 signaling in rat and cell models of acute myocardial infarction. Immunity, Inflammation and Disease 2023, 11((2)), e775. [Google Scholar] [CrossRef]
- Fu, R.-H.; Hong, S.-Y.; Chen, H.-J. Syringin Prevents 6-Hydroxydopamine Neurotoxicity by Mediating the MiR-34a/SIRT1/Beclin-1 Pathway and Activating Autophagy in SH-SY5Y Cells and the Caenorhabditis elegans Model. Cells 2023, 12((18)), 2310. [Google Scholar] [CrossRef] [PubMed]
- Majeed, Y.; Halabi, N.; Madani, A.Y.; Engelke, R.; Bhagwat, A.M.; Abdesselem, H.; Agha, M.V.; Vakayil, M.; Courjaret, R.; Goswami, N. SIRT1 promotes lipid metabolism and mitochondrial biogenesis in adipocytes and coordinates adipogenesis by targeting key enzymatic pathways. Scientific reports 2021, 11((1)), 8177. [Google Scholar] [CrossRef] [PubMed]
- Liang, D.; Zhuo, Y.; Guo, Z.; He, L.; Wang, X.; He, Y.; Li, L.; Dai, H. SIRT1/PGC-1 pathway activation triggers autophagy/mitophagy and attenuates oxidative damage in intestinal epithelial cells. Biochimie 2020, 170, 10–20. [Google Scholar] [CrossRef]
- Li, L.; Zou, J.; Zhou, M.; Li, H.; Zhou, T.; Liu, X.; Huang, Q.; Yang, S.; Xiang, Q.; Yu, R. Phenylsulfate-induced oxidative stress and mitochondrial dysfunction in podocytes are ameliorated by Astragaloside IV activation of the SIRT1/PGC1α /Nrf1 signaling pathway. Biomedicine & Pharmacotherapy 2024, 177, 117008. [Google Scholar]
- Wang, Y.; Ma, Y.; Ke, Y.; Jiang, X.; Liu, J.; Xiao, Y.; Zheng, H.; Wang, C.; Chen, X.; Shi, M. Fangji Huangqi decoction ameliorates membranous nephropathy through the upregulation of BNIP3-mediated mitophagy. Journal of Ethnopharmacology 2024, 324, 117734. [Google Scholar] [CrossRef]
- Di Micco, R.; Krizhanovsky, V.; Baker, D.; d'Adda di Fagagna, F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Biol 2021, 22((2)), 75–95. [Google Scholar] [CrossRef]
- Gorgoulis, V.; Adams, P.D.; Alimonti, A.; Bennett, D.C.; Bischof, O.; Bishop, C.; Campisi, J.; Collado, M.; Evangelou, K.; Ferbeyre, G.; Gil, J.; Hara, E.; Krizhanovsky, V.; Jurk, D.; Maier, A.B.; Narita, M.; Niedernhofer, L.; Passos, J.F.; Robbins, P.D.; Schmitt, C.A.; Sedivy, J.; Vougas, K.; von Zglinicki, T.; Zhou, D.; Serrano, M.; Demaria, M. Cellular Senescence: Defining a Path Forward. Cell 2019, 179((4)), 813–827. [Google Scholar] [CrossRef]
- Muñoz-Espín, D.; Serrano, M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol 2014, 15((7)), 482–496. [Google Scholar] [CrossRef] [PubMed]
- Wiley, C.D.; Campisi, J. The metabolic roots of senescence: mechanisms and opportunities for intervention. Nat Metab 2021, 3((10)), 1290–1301. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.; Zhou, H.; Shen, X.; Lin, X.; Zhang, Y.; Sun, Y.; Zhou, Y.; Zhang, L.; Zhang, D. The role of cellular senescence in metabolic diseases and the potential for senotherapeutic interventions. Front Cell Dev Biol 2023, 11, 1276707. [Google Scholar] [CrossRef]
- Mury, P.; Dagher, O.; Fortier, A.; Diaz, A.; Lamarche, Y.; Noly, P.E.; Ibrahim, M.; Pagé, P.; Demers, P.; Bouchard, D.; Bernier, P.L.; Poirier, N.; Moss, E.; Durrleman, N.; Jeanmart, H.; Pellerin, M.; Lettre, G.; Thorin-Trescases, N.; Carrier, M.; Thorin, E. Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients. Aging Cell 2025, 24((8)), e70108. [Google Scholar] [CrossRef]
- Hickson, L.J.; Langhi Prata, L.G.P.; Bobart, S.A.; Evans, T.K.; Giorgadze, N.; Hashmi, S.K.; Herrmann, S.M.; Jensen, M.D.; Jia, Q.; Jordan, K.L.; Kellogg, T.A.; Khosla, S.; Koerber, D.M.; Lagnado, A.B.; Lawson, D.K.; LeBrasseur, N.K.; Lerman, L.O.; McDonald, K.M.; McKenzie, T.J.; Passos, J.F.; Pignolo, R.J.; Pirtskhalava, T.; Saadiq, I.M.; Schaefer, K.K.; Textor, S.C.; Victorelli, S.G.; Volkman, T.L.; Xue, A.; Wentworth, M.A.; Wissler Gerdes, E.O.; Zhu, Y.; Tchkonia, T.; Kirkland, J.L. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. eBioMedicine 2019, 47, 446–456. [Google Scholar] [CrossRef]
- Fouqueray, P.; Bolze, S.; Dubourg, J.; Hallakou-Bozec, S.; Theurey, P.; Grouin, J.-M.; Chevalier, C.; Gluais-Dagorn, P.; Moller, D.E.; Cusi, K. Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study. Cell Reports Medicine 2021, 2((12)). [Google Scholar] [CrossRef]
- Ruderman, N.B.; Carling, D.; Prentki, M.; Cacicedo, J.M. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 2013, 123((7)), 2764–2772. [Google Scholar] [CrossRef] [PubMed]
- Hotamisligil, G.S.; Erbay, E. Nutrient sensing and inflammation in metabolic diseases. Nature Reviews Immunology 2008, 8((12)), 923–934. [Google Scholar] [CrossRef]
- Micó, V.; Berninches, L.; Tapia, J.; Daimiel, L. NutrimiRAging: micromanaging nutrient sensing pathways through nutrition to promote healthy aging. International journal of molecular sciences 2017, 18((5)), 915. [Google Scholar] [CrossRef]
- García-Martínez, B.I.; Ruiz-Ramos, M.; Pedraza-Chaverri, J.; Santiago-Osorio, E.; Mendoza-Núñez, V.M. Effect of Resveratrol on Markers of Oxidative Stress and Sirtuin 1 in Elderly Adults with Type 2 Diabetes. International Journal of Molecular Sciences 2023, 24((8)), 7422. [Google Scholar] [CrossRef]
- Ma, N.; Zhang, Y. Effects of resveratrol therapy on glucose metabolism, insulin resistance, inflammation, and renal function in the elderly patients with type 2 diabetes mellitus: A randomized controlled clinical trial protocol. Medicine 2022, 101, 32. [Google Scholar] [CrossRef]
- Orr, M.E.; Kotkowski, E.; Ramirez, P.; Bair-Kelps, D.; Liu, Q.; Brenner, C.; Schmidt, M.S.; Fox, P.T.; Larbi, A.; Tan, C.; Wong, G.; Gelfond, J.; Frost, B.; Espinoza, S.; Musi, N.; Powers, B. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. Geroscience 2024, 46((1)), 665–682. [Google Scholar] [CrossRef] [PubMed]
- Gao, Z.; Zhan, H.; Zong, W.; Sun, M.; Linghu, L.; Wang, G.; Meng, F.; Chen, M. Salidroside alleviates acetaminophen-induced hepatotoxicity via Sirt1-mediated activation of Akt/Nrf2 pathway and suppression of NF-κB/NLRP3 inflammasome axis. Life Sciences 2023, 327, 121793. [Google Scholar] [CrossRef] [PubMed]
- Rong, L.; Li, Z.; Leng, X.; Li, H.; Ma, Y.; Chen, Y.; Song, F. Salidroside induces apoptosis and protective autophagy in human gastric cancer AGS cells through the PI3K/Akt/mTOR pathway. Biomedicine & Pharmacotherapy 2020, 122, 109726. [Google Scholar]
- Wang, X.; Ren, Y.; Du, X.; Song, L.; Chen, F.; Su, F. Effects of late-onset dietary intake of salidroside on insulin/insulin-like growth factor-1 (IGF-1) signaling pathway of the annual fish Nothobranchius guentheri. Archives of Gerontology and Geriatrics 2020, 91, 104233. [Google Scholar] [CrossRef]
- Lee, Y.-J.; Lee, Y.M.; Lee, C.-K.; Jung, J.K.; Han, S.B.; Hong, J.T. Therapeutic applications of compounds in the Magnolia family. Pharmacology & therapeutics 2011, 130((2)), 157–176. [Google Scholar]
- Tian, R.; Yang, J.; Wang, X.; Liu, S.; Dong, R.; Wang, Z.; Yang, Z.; Zhang, Y.; Cai, Z.; Yang, H.; Hu, Y.; She, Z.-G.; Li, H.; Zhou, J.; Zhang, X.-J. Honokiol acts as an AMPK complex agonist therapeutic in non-alcoholic fatty liver disease and metabolic syndrome. Chinese Medicine 2023, 18((1)), 30. [Google Scholar] [CrossRef]
- Shi, M.; Lu, Y.; Wu, J.; Zheng, Z.; Lv, C.; Ye, J.; Qin, S.; Zeng, C. Beneficial Effects of Theaflavins on Metabolic Syndrome: From Molecular Evidence to Gut Microbiome. International Journal of Molecular Sciences 2022, 23((14)), 7595. [Google Scholar] [CrossRef] [PubMed]
- Zhang, W.; An, R.; Li, Q.; Sun, L.; Lai, X.; Chen, R.; Li, D.; Sun, S. Theaflavin TF3 relieves hepatocyte lipid deposition through activating an AMPK signaling pathway by targeting plasma kallikrein. Journal of Agricultural and Food Chemistry 2020, 68((9)), 2673–2683. [Google Scholar] [CrossRef] [PubMed]
- Guth, M. Stem cell exhaustion as a hallmark of aging. J Cell Sci Regener Med. 2025, 1, 20–26. [Google Scholar]
- Guerville, F.; Barreto, P.D.S.; Ader, I.; Andrieu, S.; Casteilla, L.; Dray, C.; Fazilleau, N.; Guyonnet, S.; Langin, D.; Liblau, R. Revisiting the hallmarks of aging to identify markers of biological age. The Journal of prevention of Alzheimer's disease 2020, 7((1)), 56–64. [Google Scholar] [CrossRef]
- Gunawardene, P.; Bermeo, S.; Vidal, C.; Al-Saedi, A.; Chung, P.; Boersma, D.; Phu, S.; Pokorski, I.; Suriyaarachchi, P.; Demontiero, O. Association between circulating osteogenic progenitor cells and disability and frailty in older persons: the Nepean Osteoporosis and Frailty Study. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences 2016, 71((9)), 1124–1130. [Google Scholar] [CrossRef]
- Qi, Y.; Liu, W.; Wang, X.; Lu, N.; Yang, M.; Liu, W.; Ma, J.; Liu, W.; Zhang, W.; Li, S. Adipose-derived mesenchymal stem cells from obese mice prevent body weight gain and hyperglycemia. Stem Cell Research & Therapy 2021, 12((1)), 277. [Google Scholar] [CrossRef]
- Kotikalapudi, N.; Sampath, S.J.P.; Sinha, S.N.; Bhonde, R.; Mungamuri, S.K.; Venkatesan, V. Human placental mesenchymal stromal cell therapy restores the cytokine efflux and insulin signaling in the skeletal muscle of obesity-induced type 2 diabetes rat model. Human Cell 2022, 35((2)), 557–571. [Google Scholar] [CrossRef]
- Kotikalapudi, N.; Sampath, S.J.P.; Sinha, S.N.; R, B.; Mungamuri, S.K.; Venkatesan, V. Placental mesenchymal stem cells restore glucose and energy homeostasis in obesogenic adipocytes. Cell and Tissue Research 2023, 391((1)), 127–144. [Google Scholar] [CrossRef]
- Zhang, Y.; Gao, S.; Liang, K.; Wu, Z.; Yan, X.; Liu, W.; Li, J.; Wu, B.; Du, Y. Exendin-4 gene modification and microscaffold encapsulation promote self-persistence and antidiabetic activity of MSCs. Science Advances 2021, 7((27)), eabi4379. [Google Scholar] [CrossRef]
- Zarei, M. Mesenchymal stem cell therapy for type 2 diabetes: mechanisms, clinical evidence, and future directions. Mol Biol Rep 2025, 52((1)), 1046. [Google Scholar] [CrossRef] [PubMed]
- Wu, Z.; Huang, S.; Li, S.; Cai, J.; Huang, L.; Wu, W.; Chen, J.; Tan, J. Bone marrow mesenchymal stem cell and mononuclear cell combination therapy in patients with type 2 diabetes mellitus: a randomized controlled study with 8-year follow-up. Stem Cell Res Ther 2024, 15((1)), 339. [Google Scholar] [CrossRef]
- Ivan, A.; Lukinich-Gruia, A.T.; Cristea, I.-M.; Pricop, M.-A.; Calma, C.L.; Simina, A.-G.; Tatu, C.A.; Galuscan, A.; Păunescu, V. Quercetin and Mesenchymal Stem Cell Metabolism: A Comparative Analysis of Young and Senescent States. Molecules 2024, 29((23)), 5755. [Google Scholar] [CrossRef]
- Huang, H.; Zhang, W.; Su, J.; Zhou, B.; Han, Q. Spermidine Retarded the Senescence of Multipotent Mesenchymal Stromal Cells In Vitro and In Vivo through SIRT3-Mediated Antioxidation. Stem Cells Int 2023, 2023, 9672658. [Google Scholar] [CrossRef]
- Zhu, Y.; Doornebal, E.J.; Pirtskhalava, T.; Giorgadze, N.; Wentworth, M.; Fuhrmann-Stroissnigg, H.; Niedernhofer, L.J.; Robbins, P.D.; Tchkonia, T.; Kirkland, J.L. New agents that target senescent cells: the flavone, fisetin, and the BCL-X(L) inhibitors, A1331852 and A1155463. Aging (Albany NY) 2017, 9((3)), 955–963. [Google Scholar] [CrossRef] [PubMed]
- Mullen, M.; Nelson, A.L.; Goff, A.; Billings, J.; Kloser, H.; Huard, C.; Mitchell, J.; Hambright, W.S.; Ravuri, S.; Huard, J. Fisetin Attenuates Cellular Senescence Accumulation During Culture Expansion of Human Adipose-Derived Stem Cells. Stem Cells 2023, 41((7)), 698–710. [Google Scholar] [CrossRef]
- Fafián-Labora, J.A.; O’Loghlen, A. Classical and nonclassical intercellular communication in senescence and ageing. Trends in cell biology 2020, 30((8)), 628–639. [Google Scholar] [CrossRef] [PubMed]
- van Niel, G.; Carter, D.R.; Clayton, A.; Lambert, D.W.; Raposo, G.; Vader, P. Challenges and directions in studying cell–cell communication by extracellular vesicles. Nature reviews Molecular cell biology 2022, 23((5)), 369–382. [Google Scholar] [CrossRef]
- Xu, Q.; Fu, Q.; Li, Z.; Liu, H.; Wang, Y.; Lin, X.; He, R.; Zhang, X.; Ju, Z.; Campisi, J. The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice. Nature Metabolism 2021, 3((12)), 1706–1726. [Google Scholar] [CrossRef]
- Isaac, R.; Reis, F.C.G.; Ying, W.; Olefsky, J.M. Exosomes as mediators of intercellular crosstalk in metabolism. Cell metabolism 2021, 33((9)), 1744–1762. [Google Scholar] [CrossRef] [PubMed]
- Zhang, M.; Wei, J.; He, C.; Sui, L.; Jiao, C.; Zhu, X.; Pan, X. Inter-and intracellular mitochondrial communication: signaling hubs in aging and age-related diseases. Cellular & Molecular Biology Letters 2024, 29((1)), 153. [Google Scholar]
- Jia, H.; Liu, D. Integrative single-cell analysis of metabolic syndrome reveals novel cellular heterogeneity and differentiation dynamics in adipose tissue. Diabetol Metab Syndr 2025, 17((1)), 403. [Google Scholar] [CrossRef]
- Sheng, Q.; Wu, Z.; Li, W.; Wang, L.; Xu, H.; Wang, W.; Yan, Z.; Ge, G.; Xu, Y.; Geng, D. Extracellular vesicles in metabolic perspective: mechanism and targeted therapy. J Nanobiotechnology 2025, 23((1)), 676. [Google Scholar] [CrossRef] [PubMed]
- Zisser, L.; Binder, C.J. Extracellular Vesicles as Mediators in Atherosclerotic Cardiovascular Disease. J Lipid Atheroscler 2024, 13((3)), 232–261. [Google Scholar] [CrossRef] [PubMed]
- Sandoval-Bórquez, A.; Carrión, P.; Hernández, M.P.; Pérez, J.A.; Tapia-Castillo, A.; Vecchiola, A.; Fardella, C.E.; Carvajal, C.A. Adipose Tissue Dysfunction and the Role of Adipocyte-Derived Extracellular Vesicles in Obesity and Metabolic Syndrome. Journal of the Endocrine Society 2024, 8((8)). [Google Scholar] [CrossRef]
- Matilainen, J.; Berg, V.; Vaittinen, M.; Impola, U.; Mustonen, A.-M.; Männistö, V.; Malinen, M.; Luukkonen, V.; Rosso, N.; Turunen, T. Increased secretion of adipocyte-derived extracellular vesicles is associated with adipose tissue inflammation and the mobilization of excess lipid in human obesity. Journal of translational medicine 2024, 22((1)), 623. [Google Scholar] [CrossRef]
- Li, Y.; Meng, Y.; Zhu, X.; Saadiq, I.M.; Jordan, K.L.; Eirin, A.; Lerman, L.O. Metabolic syndrome increases senescence-associated micro-RNAs in extracellular vesicles derived from swine and human mesenchymal stem/stromal cells. Cell Commun Signal 2020, 18((1)), 124. [Google Scholar] [CrossRef]
- Heiston, E.M.; Ballantyne, A.; Stewart, N.R.; La Salvia, S.; Musante, L.; Lanningan, J.; Erdbrügger, U.; Malin, S.K. Insulin infusion decreases medium-sized extracellular vesicles in adults with metabolic syndrome. American Journal of Physiology-Endocrinology and Metabolism 2022, 323((4)), E378–E388. [Google Scholar] [CrossRef]
- Li, Y.; Meng, Y.; Zhu, X.; Van Wijnen, A.; Eirin, A.; Lerman, L.O. Metabolic syndrome is associated with altered mRNA and miRNA content in human circulating extracellular vesicles. Frontiers in Endocrinology 2021, 12, 687586. [Google Scholar] [CrossRef]
- Mode, N.; Chaitanya, B. Senescence-Associated Secretory Phenotype (SASP) in Diabetes. Journal of Pharma Insights and Research 2025, 3((1)), 205–211. [Google Scholar] [CrossRef]
- Shen, X.; Li, M.; Li, Y.; Jiang, Y.; Niu, K.; Zhang, S.; Lu, X.; Zhang, R.; Zhao, Z.; Zhou, L.; Guo, Z.; Wang, S.; Wei, C.; Chang, L.; Hou, Y.; Wu, Y. Bazi Bushen ameliorates age-related energy metabolism dysregulation by targeting the IL-17/TNF inflammatory pathway associated with SASP. Chinese Medicine 2024, 19((1)), 61. [Google Scholar] [CrossRef]
- Xu, Q.; Fu, Q.; Li, Z.; Liu, H.; Wang, Y.; Lin, X.; He, R.; Zhang, X.; Ju, Z.; Campisi, J.; Kirkland, J.L.; Sun, Y. The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice. Nature Metabolism 2021, 3((12)), 1706–1726. [Google Scholar] [CrossRef] [PubMed]
- Yang, X.; Wu, W.; Huang, W.; Fang, J.; Chen, Y.; Chen, X.; Lin, X.; He, Y. Exosomes derived from baicalin-pretreated mesenchymal stem cells mitigate atherosclerosis by regulating the SIRT1/NF-κB signaling pathway. Mol Med Rep 2025, 31((5)). [Google Scholar] [CrossRef] [PubMed]
- Xu, N.; Huang, F.; Jian, C.; Qin, L.; Lu, F.; Wang, Y.; Zhang, Z.; Zhang, Q. Neuroprotective effect of salidroside against central nervous system inflammation-induced cognitive deficits: A pivotal role of sirtuin 1-dependent Nrf-2/HO-1/NF-κB pathway. Phytother Res 2019, 33((5)), 1438–1447. [Google Scholar] [CrossRef]
- Xu, J.; Li, Y. Effects of salidroside on exhaustive exercise-induced oxidative stress in rats. Mol Med Rep 2012, 6((5)), 1195–1198. [Google Scholar] [CrossRef]
- Ren, M.; Xu, W.; Xu, T. Salidroside represses proliferation, migration and invasion of human lung cancer cells through AKT and MEK/ERK signal pathway. Artif Cells Nanomed Biotechnol 2019, 47((1)), 1014–1021. [Google Scholar] [CrossRef]
- Almohawes, Z.N.; El-Kott, A.; Morsy, K.; Shati, A.A.; El-Kenawy, A.E.; Khalifa, H.S.; Elsaid, F.G.; Abd-Lateif, A.-E.-K. M.; Abu-Zaiton, A.; Ebealy, E.R. Salidroside inhibits insulin resistance and hepatic steatosis by downregulating miR-21 and subsequent activation of AMPK and upregulation of PPARα in the liver and muscles of high fat diet-fed rats. Archives of physiology and biochemistry 2024, 130((3)), 257–274. [Google Scholar] [CrossRef]
- Chiabotto, G.; Ceccotti, E.; Tapparo, M.; Camussi, G.; Bruno, S. Human liver stem cell-derived extracellular vesicles target hepatic stellate cells and attenuate their pro-fibrotic phenotype. Frontiers in Cell and Developmental Biology 2021, 9, 777462. [Google Scholar] [CrossRef] [PubMed]
- Lang, Z.; Li, Y.; Lin, L.; Li, X.; Tao, Q.; Hu, Y.; Bao, M.; Zheng, L.; Yu, Z.; Zheng, J. Hepatocyte-derived exosomal miR-146a-5p inhibits hepatic stellate cell EMT process: a crosstalk between hepatocytes and hepatic stellate cells. Cell Death Discovery 2023, 9((1)), 304. [Google Scholar] [CrossRef]
- Zhang, J.; Chen, W.; Gong, R.; Deng, J.; Sun, Q.; Yang, H. Unlocking the anti-aging potential of Lycium barbarum polysaccharides: Structure-activity insights, mechanisms, and future therapeutics. International Journal of Biological Macromolecules 2026, 343, 150242. [Google Scholar] [CrossRef]
- Zhang, T.; Alexa, E.-A.; Liu, G.; Berisha, A.; Walsh, R.; Kelleher, R. Lycium barbarum for Health and Longevity: A Review of Its Biological Significance. Obesities 2025, 5((2)), 35. [Google Scholar] [CrossRef]
- Xue, S.; Hu, X.; Zhu, L.; Nie, L.; Li, G. Protective functions of Lycium barbarum polysaccharides in H2O2-injured vascular endothelial cells through anti-oxidation and anti-apoptosis effects. Biomedical Reports 2019, 11((5)), 207–214. [Google Scholar] [CrossRef]
- Zhang, X.; Yang, X.; Lin, Y.; Suo, M.; Gong, L.; Chen, J.; Hui, R. Anti-hypertensive effect of Lycium barbarum L. with down-regulated expression of renal endothelial lncRNA sONE in a rat model of salt-sensitive hypertension. International journal of clinical and experimental pathology 2015, 8((6)), 6981. [Google Scholar]
- Qiang, X.; Xia, T.; Geng, B.; Zhao, M.; Li, X.; Zheng, Y.; Wang, M. Bioactive Components of Lycium barbarum and Deep-Processing Fermentation Products. Molecules 2023, 28, 24. [Google Scholar] [CrossRef] [PubMed]
- Yu, W.; Jie, S.; Su, G.; Zhuangwei, N.; Yiqing, Z.; Suhong, C.; Guiyuan, L. The ultrafine powder of atractylodis macrocephalae rhizoma improves immune function in naturally aging rats by regulating the PI3K/Akt/NF-κB signaling pathway. Front Pharmacol 2025, 16, 1550357. [Google Scholar] [CrossRef] [PubMed]
- Xu, X.; Zhao, Y.; Ma, H.; Hu, Y.; Yu, L.; Su, Y.; Song, J.; Xie, Z.; Zhang, Z.; Wang, P. Mechanism of Atractylodis Rhizoma in improving cognitive dysfunction in Alzheimer's disease by regulating the cAMP/CREB/BDNF pathway. Int Immunopharmacol 2026, 168 (Pt 2), 115923. [Google Scholar] [CrossRef]
- Xiang, X.; Cao, N.; Chen, F.; Qian, L.; Wang, Y.; Huang, Y.; Tian, Y.; Xu, D.; Li, W. Polysaccharide of Atractylodes macrocephala Koidz (PAMK) Alleviates Cyclophosphamide-induced Immunosuppression in Mice by Upregulating CD28/IP3R/PLCγ-1/AP-1/NFAT Signal Pathway. Front Pharmacol 2020, 11, 529657. [Google Scholar] [CrossRef] [PubMed]
- Yang, A.; Kong, L.; You, Z.; Li, X.; Guan, J.; Li, F.; Zhong, L.; Jiang, H. A review of Psoralea corylifolia L.: a valuable plant with profound biological significance. Frontiers in Pharmacology 2025, 15–2024. [Google Scholar] [CrossRef]
- Liu, J.; Lei, Z.; Wang, Z.; Wang, H.; Sun, J.; Guo, D.; Luan, F.; Zou, J.; Shi, Y. Ethnobotanical usages, phytochemistry, pharmacology, and quality control of chuanxiong rhizoma: A review. J Ethnopharmacol 2025, 337 (Pt 3), 118902. [Google Scholar] [CrossRef]
- Makgato, K.S.; Gololo, S.S.; Mncube, S.C.; Motlhatlego, K.E.; Thibane, V.S. Effect of varying exposure to abiotic stress on the metabolic profile of Monsonia angustifolia Sond. which has potential to treat Alzheimer's disease through reduction of oxidative stress. South African Journal of Botany 2025, 180, 74–82. [Google Scholar] [CrossRef]
- Tungmunnithum, D.; Drouet, S.; Garros, L.; Lorenzo, J.M.; Hano, C. Flavonoid Profiles and Antioxidant Potential of Monochoria angustifolia (G. X. Wang) Boonkerd & Tungmunnithum, a New Species from the Genus Monochoria C. Presl. Antioxidants (Basel) 2022, 11((5)). [Google Scholar]
- Aonsri, C.; Kuljarusnont, S.; Tungmunnithum, D. Discovering Skin Anti-Aging Potentials of the Most Abundant Flavone Phytochemical Compound Reported in Siam Violet Pearl, a Medicinal Plant from Thailand by In Silico and In Vitro Assessments. Antioxidants (Basel) 2025, 14((3)). [Google Scholar] [CrossRef]
- Wang, N.; Liu, J.; Xie, F.; Gao, X.; Ye, J.H.; Sun, L.Y.; Wei, R.; Ai, J. miR-124/ATF-6, a novel lifespan extension pathway of Astragalus polysaccharide in Caenorhabditis elegans. J Cell Biochem 2015, 116((2)), 242–251. [Google Scholar] [CrossRef]
- Liu, T.; Sun, Y.; Zhao, X. Research Progress on Chemical Components of Astragalus membranaceus and Treatment of Metabolic Syndrome. Molecules 2025, 30, 18. [Google Scholar] [CrossRef]
- Meng, J.; Fu, Y.; Liu, L.; Zhou, Z.; Yang, L.; Kong, L.; Guan, Y.; Zhang, G.; Sun, H.; Liu, C.; Sun, Y.; Han, Y.; Wang, X. Rapid characterization of the constituents in Jingfang Granules by ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry. Analytical Methods 2025, 17((41)), 8362–8370. [Google Scholar] [CrossRef]
- Wang, R.; Wang, Q.; Liu, M.; Xiao, H.; Zhang, G.; Yao, J.; Liu, M. Jingfang Granules for Diabetic Wound Healing: Insights from Network Pharmacology and Experimental Validation. Drug Des Devel Ther 2025, 19, 4835–4860. [Google Scholar] [CrossRef]
- Yin, X.; Meng, Y.; Sun, C.; Zhao, Y.; Wang, W.; Zhao, P.; Wang, M.; Ren, J.; Yao, J.; Zhang, L.; Xia, X. Investigation of anti-aging and anti-infection properties of Jingfang Granules using the Caenorhabditis elegans model. Biogerontology 2024, 25((3)), 433–445. [Google Scholar] [CrossRef] [PubMed]
- Gao, B.; Wang, R.; Peng, Y.; Li, X. Effects of a homogeneous polysaccharide from Sijunzi decoction on human intestinal microbes and short chain fatty acids in vitro. Journal of Ethnopharmacology 2018, 224, 465–473. [Google Scholar] [CrossRef] [PubMed]
- Yuan, Y.; Z., Y.; Zheng, R.; Yuan, H.; Zhou, R.; Jia, S.; Liu, J. Elucidating the anti-aging mechanism of Si Jun Zi Tang by integrating network pharmacology and experimental validation in vivo. Aging (Albany NY) 2022, 14, 3941–3955. [Google Scholar] [CrossRef]
- Ke, H.; Zhang, X.; Liang, S.; Zhou, C.; Hu, Y.; Huang, Q.; Wu, J. Study on the anti-skin aging effect and mechanism of Sijunzi Tang based on network pharmacology and experimental validation. J Ethnopharmacol 2024, 333, 118421. [Google Scholar] [CrossRef]
- Liu, Z.-H.; Li, S.-Y.; Li, B.-J.; Zhang, F.; Li, X.-G.; Li, X.; Zheng, J. Deciphering the Therapeutic Mechanisms of Wuzi Yanzong Pill for Asthenozoospermia: A Synergistic Approach Combining Bioinformatics and Molecular Dynamics. Cell Biochemistry and Biophysics 2025, 83((4)), 5181–5196. [Google Scholar] [CrossRef]
- Yu, Q.; Song, F.J.; Chen, J.F.; Dong, X.; Jiang, Y.; Zeng, K.W.; Tu, P.F.; Wang, X.M. Antineuroinflammatory Effects of Modified Wu-Zi-Yan-Zong Prescription in β-Amyloid-Stimulated BV2 Microglia via the NF-κB and ERK/p38 MAPK Signaling Pathways. Evid Based Complement Alternat Med 2017, 2017, 8470381. [Google Scholar] [CrossRef]
- Hang, W.; Fan, H.-j.; Li, Y.-r.; Xiao, Q.; Jia, L.; Song, L.-j.; Gao, Y.; Jin, X.-m.; Xiao, B.-g.; Yu, J.-z.; Ma, C.-g.; Chai, Z. Wuzi Yanzong pill attenuates MPTP-induced Parkinson’s Disease via PI3K/Akt signaling pathway. Metabolic Brain Disease 2022, 37((5)), 1435–1450. [Google Scholar] [CrossRef] [PubMed]
- Chen, W.Q.; Ding, C.F.; Yu, J.; Wang, C.Y.; Wan, L.Y.; Hu, H.M.; Ma, J.X. Wuzi Yanzong Pill-Based on Network Pharmacology and In Vivo Evidence-Protects Against Spermatogenesis Disorder via the Regulation of the Apoptosis Pathway. Front Pharmacol 2020, 11, 592827. [Google Scholar] [CrossRef]
- Zhang, Y.; Chen, Z.; Chen, L.; Dong, Q.; Yang, D.-H.; Zhang, Q.; Zeng, J.; Wang, Y.; Liu, X.; Cui, Y.; Li, M.; Luo, X.; Zhou, C.; Ye, M.; Li, L.; He, Y. Astragali radix (Huangqi): a time-honored nourishing herbal medicine. Chinese Medicine 2024, 19((1)), 119. [Google Scholar] [CrossRef] [PubMed]
- Liu, P.; Zhao, H.; Luo, Y. Anti-Aging Implications of Astragalus Membranaceus (Huangqi): A Well-Known Chinese Tonic. Aging Dis 2017, 8((6)), 868–886. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Feng, Q. Pharmacological Effects and Molecular Protective Mechanisms of Astragalus Polysaccharides on Nonalcoholic Fatty Liver Disease. Front Pharmacol 2022, 13, 854674. [Google Scholar] [CrossRef]
- Dong, N.; Li, X.; Xue, C.; Zhang, L.; Wang, C.; Xu, X.; Shan, A. Astragalus polysaccharides alleviates LPS-induced inflammation via the NF-κB/MAPK signaling pathway. J Cell Physiol 2020, 235((7-8)), 5525–5540. [Google Scholar] [CrossRef]
- Gong, P.; Xiao, X.; Wang, S.; Shi, F.; Liu, N.; Chen, X.; Yang, W.; Wang, L.; Chen, F. RETRACTED: Hypoglycemic effect of astragaloside IV via modulating gut microbiota and regulating AMPK/SIRT1 and PI3K/AKT pathway. Journal of Ethnopharmacology 2021, 281, 114558. [Google Scholar] [CrossRef] [PubMed]
- Pragasam, S.J.; Venkatesan, V.; Rasool, M. Immunomodulatory and anti-inflammatory effect of p-coumaric acid, a common dietary polyphenol on experimental inflammation in rats. Inflammation 2013, 36((1)), 169–176. [Google Scholar] [CrossRef]
- Peng, J.; Zheng, T.T.; Liang, Y.; Duan, L.F.; Zhang, Y.D.; Wang, L.J.; He, G.M.; Xiao, H.T. p-Coumaric Acid Protects Human Lens Epithelial Cells against Oxidative Stress-Induced Apoptosis by MAPK Signaling. Oxid Med Cell Longev 2018, 2018, 8549052. [Google Scholar] [CrossRef] [PubMed]
- An, Y.; Zhang, L.; Li, S.; Fan, X.; Tian, J.; Zhang, J.; Li, Z. p-Coumaric acid alleviates non-alcoholic fatty liver disease by promoting GLP-1 secretion via the GRP78-Ca2+ signaling axis. Food Bioscience 2025, 63, 105571. [Google Scholar] [CrossRef]
- De Stefano, A.; Caporali, S.; Di Daniele, N.; Rovella, V.; Cardillo, C.; Schinzari, F.; Minieri, M.; Pieri, M.; Candi, E.; Bernardini, S.; Tesauro, M.; Terrinoni, A. Anti-Inflammatory and Proliferative Properties of Luteolin-7-O-Glucoside. International Journal of Molecular Sciences 2021, 22((3)), 1321. [Google Scholar] [CrossRef] [PubMed]
- Wei, X.; Zhu, X.; Hu, N.; Zhang, X.; Sun, T.; Xu, J.; Bian, X. Baicalin attenuates angiotensin II-induced endothelial dysfunction. Biochemical and Biophysical Research Communications 2015, 465((1)), 101–107. [Google Scholar] [CrossRef]
- Li, H.; Zhang, Q. Research Progress of Flavonoids Regulating Endothelial Function. Pharmaceuticals 2023, 16((9)), 1201. [Google Scholar] [CrossRef]
- Yan, X.; Miao, J.; Zhang, B.; Liu, H.; Ma, H.; Sun, Y.; Liu, P.; Zhang, X.; Wang, R.; Kan, J.; Yang, F.; Wu, Q. Study on semi-bionic extraction of Astragalus polysaccharide and its anti-aging activity in vivo. Front Nutr 2023, 10, 1201919. [Google Scholar] [CrossRef]
- Li, X.; Yang, S.; Wang, S.; Shi, Y.; Dai, Y.; Zhang, X.; Liu, Y.; Guo, Y.; He, J.; Xiu, M. Regulation and mechanism of Astragalus polysaccharide on ameliorating aging in Drosophila melanogaster. Int J Biol Macromol 2023, 234, 123632. [Google Scholar] [CrossRef]
- Zhimin, C.; Mingyue, A.O.; Yujiao, L.; Lingying, Y.U.; Zhuo, Y.; Lin, H.U.; Wenbing, L.I.; Changjiang, H.U.; Yongxiang, G. Wuzi Yanzong prescription from Traditional Chinese Medicine for male infertility: a narrative review. J Tradit Chin Med 2023, 43((2)), 416–428. [Google Scholar]
- Yao, J.; Peng, T.; Shao, C.; Liu, Y.; Lin, H.; Liu, Y. The Antioxidant Action of Astragali radix: Its Active Components and Molecular Basis. Molecules 2024, 29((8)), 1691. [Google Scholar] [CrossRef]
- Yin, B.; Hou, X.W.; Lu, M.L. Astragaloside IV attenuates myocardial ischemia/reperfusion injury in rats via inhibition of calcium-sensing receptor-mediated apoptotic signaling pathways. Acta Pharmacol Sin 2019, 40((5)), 599–607. [Google Scholar] [CrossRef]
- Zhang, Z.; Fang, J.; Sun, D.; Zheng, Y.; Liu, X.; Li, H.; Hu, Y.; Liu, Y.; Zhang, M.; Liu, W.; Zhang, X.; Liu, X. Study on the Mechanism of Radix Astragali against Renal Aging Based on Network Pharmacology. Evid Based Complement Alternat Med 2022, 2022, 6987677. [Google Scholar] [CrossRef]
- Chang, X.; Chen, X.; Guo, Y.; Gong, P.; Pei, S.; Wang, D.; Wang, P.; Wang, M.; Chen, F. Advances in Chemical Composition, Extraction Techniques, Analytical Methods, and Biological Activity of Astragali Radix. Molecules 2022, 27((3)). [Google Scholar] [CrossRef]
- Ekinci Akdemir, F.N.; Albayrak, M.; Çalik, M.; Bayir, Y.; Gülçin, İ. The Protective Effects of p-Coumaric Acid on Acute Liver and Kidney Damages Induced by Cisplatin. Biomedicines 2017, 5((2)), 18. [Google Scholar] [CrossRef] [PubMed]
- Nevin, K.G.; Chacko, S.M.; Radhakrishnan, D.; Hariharan, S.; Gangadharan, A. p-Coumaric acid modulates PGC1-α and TFAM expression to protect cardiomyocytes from doxorubicin toxicity via mitochondrial biogenesis. Advances in Traditional Medicine 2025, 25((3)), 653–663. [Google Scholar] [CrossRef]
- Cui, K.; Zhang, L.; La, X.; Wu, H.; Yang, R.; Li, H.; Li, Z. Ferulic Acid and P-Coumaric Acid Synergistically Attenuate Non-Alcoholic Fatty Liver Disease through HDAC1/PPARG-Mediated Free Fatty Acid Uptake. Int J Mol Sci 2022, 23, 23. [Google Scholar] [CrossRef] [PubMed]
- Yoon, H.J.; Jung, U.J. p-Coumaric acid alleviates metabolic dysregulation in high-fructose diet-fed hamsters. Nutr Res Pract 2025, 19((2)), 200–214. [Google Scholar] [CrossRef] [PubMed]
- Goodarzi, G.; Tehrani, S.S.; Panahi, G.; Bahramzadeh, A.; Meshkani, R. Combination therapy of metformin and p-coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high-fat diet obese C57BL/6 mice. The Journal of Nutritional Biochemistry 2023, 118, 109369. [Google Scholar] [CrossRef]
- Lou, Z.; Wang, H.; Rao, S.; Sun, J.; Ma, C.; Li, J. p-Coumaric acid kills bacteria through dual damage mechanisms. Food Control 2012, 25((2)), 550–554. [Google Scholar] [CrossRef]
- United State Department of Health; Human Services. Guidance Portal, Complementary and Alternative Medicine Products and their Regulation by the Food and Drug Administration: Draft Guidance for Industry. Available online: https://www.hhs.gov/guidance/document/complementary-and-alternative-medicine-products-and-their-regulation-food-and-drug (accessed on 21January 2026).









| Herb | Main Bioactive compound | Host | Mechanism of action | Pharmacological effects | Ref. |
|---|---|---|---|---|---|
| Lycium barbarum L. | Diverse compounds | Rat, aortic endothelial cells | SIRT3/CypD pathway, AKT/eNOS signaling pathway, SOD activity, Bcl-2 expression, Bax levels, reduced lncRNA sONE expression | Immunomodulatory, antioxidant, neuroprotective, blood pressure regulation, antiaging, hypoglycemic, immunomodulator | [410,411,412,413,414] |
| Atractylodis Rhizoma | ND | AD rats, HT22 cells | cAMP-dependent pathway, PI3K/Akt/NF-κB signaling pathway | Neuroinflammation, reduce inflammatory response, enhance immune function, potentially delay aging | [415,416,417] |
| Psoralea corylifolia and Rubus chingii Hu complex | Bakuchiol, isopentenyl flavonoids, Psoralen | Mice | Wnt/β-catenin, PI3K/Akt, PPAR-γ/Wnt, NF-κB and RANKL/RANK/MAPK signaling pathways, p38 MAPK and ERK pathways | Antiosteoporosis effects, anti-inflammatory properties, neuroprotective, inhibits oxidative stress, induces apoptosis | [418,419] |
| Monochoria angustifolia | Diverse compounds | In silico and in vitro, mice | Hydrogen atom transfer mechanisms | Antioxidative, prevents neuroinflammation or neurotoxic accumulation | [420,421,422] |
| Astragalus membranaceus | Diverse compounds | In vitro, in vivo | Increases SOD activity, reduce malondialdehyde (MDA) levels, senescence (AMPK/mTOR), miR-124–regulated ATF-6 | Immunomodulatory, antihyperglycemic, antioxidant, anti-aging, anti-inflammatory | [423,424] |
| Jingfang Granule | Diverse compounds | Rat | AKT1, EGFR, MAPK3, MAPK1, IL6, and TNF and the PI3K-AKT and MAPK signaling pathways | Antioxidant, anti-inflammatory, proangiogenic, promotes wound healing in diabetic rat | [425,426,427] |
| Si Jun Zi Tang | glycyrrhizin, ginsenoside Rg5, ginsenoside Rh2, liquiritin, polyporenic acid C, atractylenolide II | In vitro, in vivo | PI3K-AKT and p38 MAPK, reduces p53, p-p53, and p21, modulates cellular senescence signaling | anti-aging, antioxidant, immunomodulator, antiapoptotic | [428,429,430] |
| Wuzi Yanzong Pill | Diverse compounds | In vitro, in vivo | PI3K/AKT signaling, TP53, TNF-α, AKT1, NF-κB, and IκBα, increase superoxide dismutase | Antiapoptotic, neuroprotective, anti-inflammatory increases secretion of neurotrophic factors, restores metabolic imbalance | [431,432,433,434] |
| Astragali radix | Diverse chemical constituents | In vitro, in vivo | MyD88-independent pathway, NF-κB/Rel, elevation of the expression of IL-17F, IL-17A, IFN-γ, IL-22, increases superoxide dismutase, inhibits the MAPK and NF-κB pathways, Wnt signaling pathway, AMPK/SIRT1 and PI3K/AKT | Gut microbial modulation, reduces Mash, anti-inflammatory, reduces oxidative stress, antiaging | [435,436,437,438,439] |
| P-coumaric acid | 4-hydroxycinnamic acid derivative | In vitro, in vivo | Inhibits NF-κB activation, MAPK, facilitates GLP-1 secretion, increases glucose-regulated protein 78 kDa (GRP78) expression |
Anti-inflammatory, antioxidant, improves MASLD, boosts mitochondrial biogenesis | [440,441,442] |
| Flavonoids | Diverse chemical constituents | In vitro, in vivo | Reduces JAK/STAT3, Nox4/ROS-NF-κB, and MAPK, PI3K/AKT/eNOS |
Antioxidant, anti-inflammatory, and anti-aging, proliferative effect | [443,444,445] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
